+

WO1993012809A1 - Inhibition competitive du recepteur alpha4-beta1 a avidite elevee a l'aide du tripeptide ldv - Google Patents

Inhibition competitive du recepteur alpha4-beta1 a avidite elevee a l'aide du tripeptide ldv Download PDF

Info

Publication number
WO1993012809A1
WO1993012809A1 PCT/US1992/011191 US9211191W WO9312809A1 WO 1993012809 A1 WO1993012809 A1 WO 1993012809A1 US 9211191 W US9211191 W US 9211191W WO 9312809 A1 WO9312809 A1 WO 9312809A1
Authority
WO
WIPO (PCT)
Prior art keywords
adhesion
cells
cell
fibronectin
peptide
Prior art date
Application number
PCT/US1992/011191
Other languages
English (en)
Inventor
Elizabeth A. Wayner
Original Assignee
Fred Hutchinson Cancer Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Research Center filed Critical Fred Hutchinson Cancer Research Center
Publication of WO1993012809A1 publication Critical patent/WO1993012809A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Definitions

  • the present invention is directed to a method of preventing migration of cells expressing high-avidity ⁇ 4 ⁇ 1 into tissues, by administering a peptide consisting essentially of LDV, to prevent adhesion of cells expressing high-avidity ⁇ 4 ⁇ 1 to a cell or extracellular matrix bearing a ligand for ⁇ 4 ⁇ 1.
  • R specific cell surface receptors for extracellular matrix (ECM) components such as collagen, fibronectin and laminin have been described (reviewed by Hynes, 1987, Cell, 48:549-554; Hemler, 1988, Immunol. Today, 9:109).
  • ECMRs have been identified using these techniques. Using monoclonal antibodies, Wayner and Carter (1987, J. Cell Biol. 105:1873-1884) identified two classes of cell surface receptors for native collagen in human fibrosarcoma cells; class I was involved in cell adhesion to collagen, fibronectin and laminin, whereas class II was involved in cell adhesion only to native collagen. Wayner et al. (1988, J. Cell Biol.
  • a complex comprising at least three glycoproteins was isolated from chicken embryo fibroblasts, using monoclonal antibodies which block cell adhesion to fibronectin (Knudsen et al., 1985, Exp. Cell Res. 157:218-226; Chen et al., 1985, J. Cell Biol. 100:1103-1114) whereas a complex of two glycoproteins was isolated from mammalian cells using vitronectin affinity chromatography (Pytela et al., 1985, Proc. Natl. Acad. Sci. U.S.A. 82:5766-5770; Pytela et al., 1986, Science 231:1559-1562).
  • Major platelet surface glycoproteins lIb and IIIa have been found to exist as a noncovalent 1:1 complex in the platelet membrane (lennings and Phillips, 1982, J. Biol. Chem. 257:10458-10463) and to serve as an ECMR for fibrinogen (Bennett et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:2417-2421; Marguerie et al., 1984, Eur. J. Biochem.
  • the ECMRs are members of the integrin family of cell adhesion molecules and possess unique a subunits complexed to the integrin ⁇ 1 subunit (Hynes, 1987, Cell 48:549-554; Wayner and Carter, 1987, J. Cell Biol. 105:1873-1884; Wayner et al., 1988, J. Cell Biol., 107:1881-1891). Additional members of the integrin receptor family include leukocyte adhesion proteins and the VLA antigens.
  • the leukocyte adhesion proteins include LFA-1, Mac-1, and P150/95, and are dimeric glycoproteins composed of different ⁇ chains and a common, 95 kDa ⁇ chain, (Kishiomoto et al., 1987, Cell 48:681-690).
  • VLA antigens are named for their very late appearance on cultured T lymphocytes (Hemler et al., 1983, J. Immunol. 131:334-340; Hemler et al., 1984, J. Immunol. 132:3011-3018; Hemler et al., 1985, Eur. J. Immunol. 15:502-508).
  • ECMR VI is identical to the prototype fibronectin receptor (Pytela et al., 1985, Cell, 40:191-198), ⁇ 5 ⁇ 1, platelet glycoprotein (gp) Ic/IIa and VLA 5, ECMR II is identical to ⁇ 2 ⁇ 1, platelet glycoprotein Ia/IIa and VLA 2 (Hemler et al., 1987, J. Biol.
  • ECMR I is identical to ⁇ 3 ⁇ 1 and VLA 3 (Kunicki et al., 1988, J. Biol. Chem., 263:4516-4519; Takada et al., 1988, J. Cellular Biochem., 37:385-393; Wayner et al., 1988, J. Cell Biol. 107:1881-1891).
  • Monoclonal antibodies to ⁇ 2 ⁇ 1, ⁇ 3 ⁇ 1 and ⁇ 5 ⁇ 1 P1H5, P1D6 and P1B5 inhibit fibroblast or platelet adhesion to collagen, fibronectin and laminin-coated surfaces (Kunicki et al., 1988, J. Cell Biol. 107: 1881-1891; Wayner et al., 1988, supra).
  • Table I lists some of the members of the integrin family described supra, and Table II lists a number of monoclonal antibodies that recognize various ECMRs.
  • the ⁇ 1 integrins are differentially expressed in cultured cells and tissue, and demonstrate clear differences in activation dependent expression.
  • expression of ⁇ 5 ⁇ 1 in hematopoietic cells is restricted to subpopulations of thymocytes and peripheral blood lymphocytes, monocytes, acute lymphocytic or myelogenous leukemias, activated T cells, migrating hemopoietic precursor cells, and some cultured T, B or erythroleukemia cell lines (Bernardi et al., 1987, J. Cell Biol., 105:489-498; Cardarelli et al., 1988, J.
  • Fibronectin is a protein found in the extracellular matrix as well as in plasma and on the surface of certain types of cells (Akiyama and Yamada, 1987, Adv. Enzymol. 59:1-57).
  • fibronectin exists as a glycoprotein heterodimer consisting of two similar subunits (called A and B chains), each having a molecular weight of approximately 220 kDa (Akiyama and Yamada, 1987, Adv. Enzymol. 59:1-57; Erickson et al., 1981, J. Cell Biol. 91:673-678).
  • Multiple specialized intramolecular domains (Ruoslahti et al., 1981, J. Biol. Chem.
  • fibronectin molecule may be cleaved into fragments which, in turn, are capable of interacting with collagen, fibrin, heparin, and cell surfaces in a manner analogous to that of the intact molecule (Hynes and Yamada, 1982, J. Cell Biol. 95:369-377).
  • Cellular and plasma fibronectin heterodimers comprise similar but not identical polypeptides.
  • the variability in the structure of fibronectin subunits derives from variations in fibronectin mRNA primary sequence due to alternative splicing in at least 2 regions of the pre-fibronectin mRNA (the ED and IIICS regions).
  • Fibronectin is capable of promoting adhesion of a variety of cell types, such as fibroblasts (Grinell et al., 1977, Exp. Cell Res. 110: 175-210), macrophages (Bevilacque et al., 1981, J. Exp. Med. 153:42-60), polymorphonuclear leukocytes (Marino et al., 1985, J. Lab. Clin. Med. 105:725-730), platelets (Koteliansky et al., 1981, Fed. Euro. Biochem. Soc. 123:59-62) and keratinocytes (Clark et al., 1985, J. Invest. Dermatol.
  • fibroblasts Grinell et al., 1977, Exp. Cell Res. 110: 175-210
  • macrophages Bevilacque et al., 1981, J. Exp. Med. 153:42-60
  • polymorphonuclear leukocytes Marino et al.,
  • lymphoid cells Brown and Juliano, 1986, J. Cell Biol. 103:1595-1603; platelets (Pytela et al., 1986, Science 228:1559-1562; Gardner and Hynes, 1985, Cell 42:439-448), muscle cells (Horowitz et al., 1985, J. Cell Biol. 101:2134-2144; Dambsky et al., 1985, J. Cell Biol. 100:1528-1539; Chapman, 1984, J. Cell Biochem. 259:109-121), and osteosarcoma cells (Pytela et al., 1985, Cell 40:191-198).
  • fibronectin binding may be competitively inhibited by fragments of fibronectin (Akiyama et al., 1985, J. Biol. Chem. 260:13256-13260).
  • RGDS tetrapeptide Arg-Gly-Asp-Ser
  • Adhesive interactions between cells have been found to occur during many important biological events, including tissue differentiation, growth and development, and also appear to play a critical role in the pathogenesis of various diseases (Humphries et al., 1986, J. Cell Biol. 103:2637-2647; Grinnell, 1984, J.
  • lymphoid cells demonstrate a preference for the type of secondary lymphoid organ that they will enter.
  • lymphocytes In trafficing through a secondary lymphoid organ, lymphocytes must first bind to the vascular endothelium in the appropriate post-capillary venules, then open up the tight junctions between endothelial cells, and finally migrate into the underlying tissue.
  • homing Migration of recirculating lymphocytes from blood into specific lymphoid tissues, called homing, has been associated with complementary adhesion molecules on the surface of the lymphocytes and on the endothelial cells of the high endothelial venules.
  • adherence of polymorphonuclear leukocytes to vascular endothelium is believed to be a key event in the development of an acute inflammatory response, and appears to be required for an effective chemotactic response as well as certain types of neutrophil-mediated vascular injury (Zimmerman and Mclntyre, 1988, J. Clin. Invest.
  • CD18 complex is identical to the ⁇ 2 integrin subfamily (supra) .
  • lymphocyte sub-populations localize in different anatomical sites; for example, immature T cells localize in the thymus.
  • IgA-producing B cells are observed to localize in the intestinal mucosa (Parrott, 1976, Clin. Gastroenterol. 5:211-228).
  • IgG-producing B cells localize primarily in lymph nodes, from which IgG is secreted into the systemic circulation (Parrott and deSousa, 1966, Nature 212:1316-1317). T cells appear to be more abundant in skin epidermis than in mucosal linings (Cahill et al., 1977, J. Exp. Med. 145:420-428).
  • LAD leukocyte adhesion deficiency
  • Various studies have indicated that the molecular defect associated with LAD results in either lack of synthesis of the common ⁇ chain or normal rate of synthesis followed by rapid degradation (Liowska- Grospierre et al., 1986, Eur. J. Immunol. 16:205; Diamanche et al., 1987, Eur. J. Immunol. 17:417).
  • ECMRs have also been observed to be associated with functions outside of the immune system. Loss of the IIb/IIIa platelet surface glycoprotein complex appears to result in defective platelet function in a genetic disease known as Glanzmann's thrombasthenia, (Hynes, 1987, Cell 48:549-554). Humphries et al. (1988, J. Cell Biol. 106:1289-1297) observed that neurons of the peripheral nervous system were able to extend neurites onto substrates bearing both the central cell-binding domain and the mCS region of fibronectin. Furthermore, we have recently shown that neurite formation on laminin or fibronectin can be inhibited by antibodies to ECMRs.
  • the present invention relates to a method for inhibiting the adhesion of one cell to another comprising interfering with the interaction between the extracellular matrix receptor and its ligand.
  • the invention is based upon the discovery that the ⁇ 4 ⁇ 1 extracellular matrix receptor promotes adhesion of lymphocytes to endothelial cells via attachment to a defined peptide sequence.
  • the ligand of the ⁇ 4 ⁇ 1 receptor had not been identified, nor had the function of the ⁇ 4 ⁇ 1 receptor in lymphocyte attachment been known.
  • the present invention enables, for the first time, specific intervention in the migration of lymphocytes through the vascular endothelium and into tissues.
  • the present invention therefore, has particular clinical utility in suppression of the immune response; in various specific embodiments of the invention, the adherence of lymphocytes to endothelium may be inhibited systemically, or may, alternatively, be localized to particular tissues or circumscribed areas. Accordingly, the present invention provides for treatment of diseases involving autoimmune responses as well as other chronic or relapsing activations of the immune system, including allergy, asthma, and chronic inflammatory skin conditions.
  • the ⁇ 4 ⁇ 1 integrin is a lymphocyte receptor for the carboxy terminal cell binding domain (CTCBD) of fibronectin which comprises adhesion sites in Hep 2 and a high affinity site, CS-1, in the type lII connecting segment or V (for variable) region.
  • CTCBD carboxy terminal cell binding domain
  • CS-1 high affinity site
  • V for variable region
  • LDV minimal peptides are either not active, or are 10-20 times less active than intact CS-1 in promoting the adhesion of lymphocytes that express a resting form of the ⁇ 4 ⁇ 1 receptor.
  • LDV minimal peptides and CS-1 were equally effective in promoting cell adhesion and spreading.
  • the avidity of the resting form of the ⁇ 4 ⁇ 1 receptor complex could be altered by treating the cells with a specific class of monoclonal antibodies to ⁇ 1 that specifically activated ⁇ 1 dependent cell adhesion.
  • the high avidity form of the ⁇ 4 ⁇ 1 receptor complex could be induced on U937 cells, T and B lymphoblastoid cell lines, or PHA stimulated T cell blasts by treating with the specific monoclonal antibodies to ⁇ 1. Resting PBL could not be induced with the antibodies to ⁇ 1 to bind to the LDV minimal peptides implying that two signals are required for LDV recognition by resting T cells. Although numerous cell populations can interact with intact CS-1 only cells which express an active ⁇ 4 ⁇ 1 receptor complex can bind the LDV sequence.
  • Peptide sequences defined herein are represented by the one-letter symbols for amino acid residues as follows: A (alanine), R (arginine), N (asparagine), D (aspartic acid), C (cysteine), Q (glutamine), E (glutamic acid), G (glycine), H (histidine), I (isoleucine), L (leucine), K (lysine), M (methionine), F (phenylalanine), P (proline), S (serine), T (threonine), W (tryptophan), Y (tyrosine), V (valine).
  • FIGURE 1 Adhesion of T lymphocytes (Molt 4), K562-1, RD or HT1080 cells to plasma fibronectin, inhibition with P1D6 monoclonal antibody and cell surface expression of ⁇ 5 ⁇ 1.
  • 51 Cr-labeled cells (10 5 cells/ml) were incubated with P1D6 monoclonal antibody (50 ⁇ g/ml) for 60 minutes at 4°C and allowed to attach to fibronectin- coated (20 ⁇ g/ml) plastic surfaces in the presence of P1D6 (solid bars) or mouse IgG (open bars) for 30 min (HT1080 or RD) or 4 hr (Molt 4 or K562) at 37°C.
  • Adhesion to plasma fibronectin (pFN) is expressed as 51 Cr cpm bound to the plastic surfaces.
  • Cell surface expression of ⁇ 5 ⁇ 1 was determined by flow cytometry by staining of cells in suspension with P1D6 monoclonal antibody.
  • Log P1D6 fluorescence (striped bars) is expressed as mean channel number (0-255) above background: right abscissa, log P1D6 fluorescence; left abscissa, pFN adhesion (cpm x 10 -3 ); ordinate, cell line.
  • FIGURE 2 Immune precipitation of lymphocyte fibronectin receptor from HT10890, Molt 4 or chronically activated CD8+ T (LAK) cell detergent extracts.
  • 125 I-labeled Molt 4, LAK or HT1080 cells were extracted with 1% Triton X-100 in the presence of phenylmethyl sulfonyl fluoride (1 mM), N-ethylmaleimide (1 mM), leupeptin (1 ⁇ g/ml) and d ⁇ sopropyl fluorophosphate (1 mM) as protease inhibitors. Aliquots of these extracts were immune precipitated with monoclonal antibodies directed to ⁇ 3 ⁇ 1 (P1B5), ⁇ 2 ⁇ 1 (P1H5) and ⁇ 4 ⁇ 1 (P3E30. The immune precipitated antigens were run on 7.5% SDS-PAGE gels in the absence of 2-ME and visualized by autoradiography. The three bands immune precipitated with P3E3 from T lymphocytes are indicated (arrows).
  • FIGURE 3 Identification of lymphocyte specific fibronectin receptor as Integrin ⁇ 4 ⁇ 1.
  • 125 I-surface labeled Jurkat cells were extracted with 0.3% CHAPS in the presence of 1 mM CaCI 2 , 1 mM diisopropyl-fluorophosphate, 1 mM phenylmethyl sulfonyl fluoride, 1mM N-ethylmaleimide, 1 ⁇ g/ml leupetin and 2 ⁇ g/ml soybean trypsin inhibitor. Aliquots of the extracts were then immune precipitated with myeloma (SP2) culture supernatant or with monoclonal antibodies P3E3, P4C2, P4G9 or with P1D6 (anti- ⁇ 5 ⁇ 1).
  • SP2 myeloma
  • the immune precipitates were run on 8% SDS-PAGE gels in the absence of reducing agent and visualized by autoradiography. Molecular weight markers are shown on the left-hand side. The ⁇ 5 and ⁇ 1 subunits are indicated as are the bands present in immune precipitates prepared with P3E3, P4C2 and P4G9 (arrows).
  • FIGURE 4 Localization of ⁇ 4 ⁇ 1 and ⁇ 5 ⁇ 1 in focal adhesions on fibronectin- coated surfaces.
  • FIGURE 4A and FIGURE 4C show focal adhesions (arrows) visualized by interference reflexion microscopy when RD cells are adhered to fibronectin.
  • FIGURE 4B shows the reorganization of the
  • FIGURE 4D shows the reorganization of ⁇ 4 ⁇ 1 stained with P4G9 (FITC) also to the focal adhesions when RD cells are adhered to fibronectin (arrows).
  • FIGURES 4A and 4B are the same field and FIGURES 4C and 4D are the same field.
  • FIGURE 5A Domain structure of human plasma fibronectin (pFN) showing the origin of the fragments used in this study.
  • FIGURE 5B SDS-PAGE gel analysis (10% acrylamide) demonstrating the purity of the fragments.
  • the 80 kDa fragment had the N-terminal amino acid sequence SD()VPSPR()LQF, and therefore begins at position 874 of the fibronectin molecule (Komblihtt et al., 1985, EMBO J. 4:1755-1759).
  • This fragment contains the cell binding domain (Cell) and the RGDS sequence of fibronectin ( ⁇ , FIGURE 5 A and FIGURE 9A).
  • the 58 kDa and 38 kDa fragments had the N-terminal amino acid sequence TAGPDQTEMTIEGLQ. Both fragments contain the C-terminal Heparin binding domain (Hep II) and result from a different cleavage of the two fibronectin chains by trypsin.
  • Hep II C-terminal Heparin binding domain
  • the 38 kDa fragment comprises the first 67 amino acid residues of the alternatively spliced connecting segment of fibronectin (IIICS) (Garcia-Pardo, 1987, Biochem. J., 241:923-928) and it is therefore derived from the A chain.
  • IIICS alternatively spliced connecting segment of fibronectin
  • the 38 kDa fragment does not contain the REDV adhesion site recognized by B16-F10 melanoma cells (Humphries et al., 1986, supra: Humphries et al., 1987, supra).
  • the 58 kDa fragment is also derived from the B chain of fibronectin and lacks the IIICS region (Garcia-Pardo, et al., 1989, EMBO J., submitted).
  • the 58 kDa fragment also contains the C-terminal fibrin binding domain of fibronectin (Fib II), and is similar to previously reported fragments from this region of plasma fibronectin (Click, E. M., and Balian, G. 1985, Biochem., 24:6685- 6696). The bands are visualized by a silver strain.
  • Fib II C-terminal fibrin binding domain of fibronectin
  • FIGURE 6 Adhesion of hematopoietic cells to plasma fibronectin and the purified 38 kDa and 80 kDa tryptic fragments of plasma fibronectin-
  • FIGURE 6A 51 Cr-labeled K562 (eiythroleukemia); FIGURE 6B, Jurkat (CD3+ T lymphocyte); and FIGURE 6C, YT (CD3- T lymphocyte) cells (10 5 /well) were allowed to adhere to plastic surfaces that had been coated with intact plasma fibronectin (pFN) or the purified 80 kDa and 38 kDa tryptic fragments at the indicate concentrations for 2 hours at 37°C. At the end of this time non-adherent cells were washed off and the bound cells were solubilized in SDS/NaOH and quantitated.
  • pFN plasma fibronectin
  • FIGURE 7 Effect of the monoclonal antibodies P1D6 and P4C2 to the integrin receptors ⁇ 5 ⁇ 1 and ⁇ 4 ⁇ 1 (respectively) on adhesion of T lymphocytes to intact plasma fibronectin (FIGURE 7A) (pFN) or the purified 80 kDa (FIGURE 7B) and 38 kDa tryptic fragments (FIGURE 7C): abscissa, cell adhesion, 51 Cr (cpm x 10 -3 ); ordinate, concentration ( ⁇ g/ml).
  • 51 Cr-labeled Molt 4 cells were incubated with purified P1D6 or P4C2 monoclonal antibodies (50 ⁇ g/ml) or purified mouse IgG (50 ⁇ g/ml) for 1 hour at 4°C. They were then allowed to adhere to plastic surfaces that had been coated with intact plasma fibronectin, or the 80 kDa and 38 kDa tryptic fragments at the indicated concentrations for 1 hour. At the end of this time the non-adherent cells were washed off and the adherent cells were solubilized and bound 51 Cr cpm were quantitated in a gamma counter. The results are expressed as bound cpm.
  • FIGURE 8 Effect of CS-1 B12 peptide on T lymphocyte adhesion to IL-1 ⁇ Activated HUVE cells.
  • FIGURE 9A Diagram of the in CS and CS-1 regions.
  • FIGURE 9B Amino acid sequence of CS-1, A13, and B12.
  • FIGURE 10 Adhesion of Jurkat T lymphoblastoid cells to plasma fibronectin, fragments of plasma fibronectin, or CS-1-rsa peptide-coated surfaces in the presence of inhibitory anti-integrin monoclonal antibodies (Mabs): solid bars, P1D6 anti- ⁇ 5 ; stippled bars, P4C2 anti- ⁇ 4 ; and hatched bars, P4C10 anti- ⁇ 1 ; abscissa, Jurkat cell adhesion (% of control); and ordinate, adhesion surface (10 ⁇ g/ml).
  • Mabs inhibitory anti-integrin monoclonal antibodies
  • FIGURE 11 Adhesion of Jurkat (Panel A) or A375 melanoma cells (Panel B) to plasma fibronectin (pFN), CS-1, A13, or EILDVPST-coated surfaces: abscissa, cell adhesion (cpm x 10 -3 ); and, ordinate, cell line.
  • FIGURE 12 Adhesion of various hematopoetic cell lines to CS-1 (open bars) or LDV (hatched bars) coated surfaces: abscissa, cell adhesion (cpm x 10 -3 ); and ordinate, cell line.
  • FIGURE 13A Adhesion of Jurkat cells to surfaces coated with pFN, CS-1, A13, or B12 derived peptide-rsa conjugates in the presence of monoclonal antibody 8A2; adhesion in the presence of purified non-immune mouse IgG (5 ug/ml): abscissa, Jurkat cell adhesion (cpm x 10 -3 ); and ordinate, adhesion surface.
  • FIGURE 13B Adhesion of Jurkat cells to surfaces coated with pFN, CS-1, A13, or B12 derived peptide-rsa conjugates in the presence of monoclonal antibody 8A2; adhesion in the presence of purified non-immune mouse IgG (5 ug/ml): abscissa, Jurkat cell adhesion (cpm x 10 -3 ); and ordinate, adhesion surface.
  • FIGURE 13B Adhesion of Jurkat cells to surfaces coated with pFN, CS-1, A13,
  • FIGURE 14A Adhesion of U937 cells to surfaces coated with pFN, CS-1, A13, or B12 derived peptide-rsa conjugates in the presence of monoclonal antibody 8A2; adhesion in the presence of purified non-immune mouse IgG (5 ug/ml): abscissa, U937 cell adhesion (cpm x 10 -3 ); and ordinate, adhesion surface.
  • FIGURE 14B Adhesion of U937 cells to surfaces coated with pFN, CS-1, A13, or B12 derived peptide-rsa conjugates in the presence of monoclonal antibody 8A2; adhesion in the presence of Mab 8A2 (5 ug/ml): abscissa, U937 cell adhesion (cpm x
  • FIGURE 15 A Adhesion of HUT 78 cells to surface coated with pFN, CS-1, A13, or B12 derived peptide-rsa conjugates in the presence of Mab 8A2; adhesion in the presence of purified non-immune mouse IgG (5 ug/ml): abscissa, HUT 78 cell adhesion (cpm x 10 -3 ); and ordinate, adhesion surface.
  • FIGURE 15B Adhesion of HUT 78 cells to surface coated with pFN, CS-1,
  • FIGURE 16 Adhesion of ⁇ 1 activated Jurkat or U937 cells to LDVPST-coated surfaces in the presence of inhibitory monoclonal antibodies to ⁇ 4 (P4C2) or ⁇ 1 (P4C10): open bars, Jurkat cells; hatched bars, U937 cells; abscissa, cell adhesion (cpm x 10 -3 ); and ordinate, monoclonal antibody.
  • P4C2 inhibitory monoclonal antibodies to ⁇ 4
  • P4C10 ⁇ 1
  • FIGURE 17 Kinetic analysis of U937 cell adhesion to LDV-peptide coated surfaces in the presence of Mab 8A2 (closed circles) or control (open circles): abscissa, U937 cell adhesion (cpm x 10 -3 ); and ordinate, time (minutes).
  • FIGURE 18A Adhesion of 72 hr PHA stimulated T cell blasts to pFN, CS-1, A13, or B12 and derivative peptide-coated surfaces; adhesion in the presence of purified non-immune mouse IgG (5 ug/ml): abscissa, PHA-activated T cell adhesion (cpm x 10 -3 ); and ordinate, adhesion surface.
  • FIGURE 18B Adhesion of 72 hr PHA stimulated T cell blasts to pFN, CS-1,
  • A13, or B12 and derivative peptide-coated surfaces adhesion in the presence of Mab 8A2 (5 ug/ml): abscissa, PHA-activated T cell adhesion (cpm x 10 -3 ); and ordinate, adhesion surface.
  • T lymphocyte adhesion to fibronectin could only be partially inhibited by P1D6 or RGD containing peptides suggesting the involvement of other receptors for fibronectin in the adhesion process.
  • adhesion of other cells to fibronectin such as malignant or transformed fibroblasts and activated T lymphocytes (LAK cells) could be completely inhibited by P1D6. This suggested that resting peripheral blood T lymphocytes and cultured T cell Ieukemias express multiple independent and functional fibronectin receptors.
  • an alternative fibronectin receptor was identified by preparing monoclonal antibodies that specifically inhibited the adhesion of T lymphocytes but not other cells to fibronectin. This receptor was identical to the integrin receptor, ⁇ 4 ⁇ 1, and mediated the attachment of peripheral cells
  • T lymphocytes expressed a clear preference for a 38 kDa tryptic fragment of plasma fibronectin (Garcia-Pardo et al., 1987, Biochem. J., 241:923-928) containing the Heparin II domain and 67 amino acid residues of the type in connecting segment (IIICS) spanning the CS-1, CS-2 and CS-3 regions defined by Humphries et al., 1986, J. Cell. Biol., 103:2637-2647; Humphries et al., 1987, J. Biol. Chem., 262:6886-6892).
  • IIICS connecting segment
  • T lymphocytes were found to attach only to CS-1 and monoclonal antibodies to ⁇ 4 ⁇ 1 (P3E3, P4C2 P4G9) completely inhibited T lymphocyte adhesion to the 38 kDa fragment and to CS-1.
  • T lymphocytes were also found to attach (with much lower affinity) to a site present in the Heparin II domain and monoclonal antibodies to ⁇ 4 ⁇ 1 also inhibited this interaction.
  • the functionally defined monoclonal antibodies to ⁇ 4 ⁇ 1 did not inhibit T lymphocyte adhesion to an 80 kDa tryptic fragment of plasma fibronectin containing the RGD sequence, whereas antibodies to ⁇ 5 ⁇ 1 (the prototype fibronectin receptor) completely inhibited this interaction.
  • the present invention relates to the discovery that the ⁇ 4 ⁇ 1 receptor mediates the interaction between lymphocytes and endothelial cells.
  • antibodies or peptides can be used to block the adhesion of lymphocytes to endothelial cells.
  • Preparation of antibodies to extracellular matrix receptors may be performed using any method for generating antibodies known in the art. Intact cells, or purified extracellular matrix receptor (ECMR) may be used as immunogen. Immunization of a host is preferably performed using immunogen obtained from a xenogenic source. Antibodies may be polyclonal or monoclonal.
  • adjuvants may be utilized to increase the immunological response, depending on the host species, and including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum.
  • BCG Bacille Calmette-Guerin
  • Corynebacterium parvum bacille Calmette-Guerin
  • a monoclonal antibody to an epitope of a ECMR can be prepared by using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include but are not Emited to the hybridoma techniques originally described by Kohler and Milstein (1975, Nature 256:495-497) and Taggart and Samloff (1983, Science 219:1228-1230), and the more recent human B cell hybridoma technique (Kozbor et al., 1983, Immunology Today 4:72) and EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96).
  • the monoclonal antibodies for therapeutic use may be human monoclonal antibodies or chimeric human-mouse (or other species) monoclonal antibodies.
  • Human monoclonal antibodies may be made by any of numerous techniques known in the art (e.g., Teng et al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:7308-7312; Kozbor et al., 1983, Immunology Today 4:72-79; Olsson et al., 1982, Meth. Enzymol. 92:3-16).
  • Chimeric antibody molecules may be prepared containing a mouse antigen-binding domain with human constant regions (Morrison et al., 1984, Proc. Natl. Acad. Sci. U.S.A. 81:6851, Takeda et al., 1985, Nature 314:452).
  • a molecular clone of an antibody to an ECMR epitope can be prepared by known techniques. Recombinant DNA methodology (see e.g., Maniatis et al., 1982, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York) may be used to construct nucleic acid sequences which encode a monoclonal antibody molecule, or antigen binding region thereof.
  • Antibody molecules may be purified by known techniques, e.g.. immunoabsorption or immunoaffinity chromatography, chromatographic methods such as HPLC (high performance Equid chromatography), or a combination thereof, etc.
  • Antibody fragments which contain the idiotype of the molecule can be generated by known techniques.
  • such fragments include but are not Emited to: the F(ab') 2 fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab') 2 fragment, and the 2 Fab or Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent.
  • antibodies which are reactive with ECMRs produced by the above methods may be identified and selected by any technique known in the art. For example, antibodies may be shown to bind to and/or immunoprecipitate a known ECMR which has been purified or otherwise separated from other proteins, as in a polyacrylamide gel. Alternatively, antibodies to ECMRs may be identified by their ability to compete with previously known ECMR antibodies for binding to ECMRs. Antibodies which bind to ECMRs may also be identified by their ability to block an ECMR/ligand interaction.
  • cells bearing an ECMR receptor which binds to fibronectin may be shown to adhere to a substrate coated with fibronectin. If an antisera or hybridoma supernatant may be shown to inhibit the adherence of cells to the substrate, the antibodies contained in antisera or supernatant may recognize the ECMR receptor.
  • antibodies which recognize the ⁇ 4 ⁇ 1 receptor may be prepared by the methods outlined supra.
  • monoclonal antibodies directed toward ⁇ 4 ⁇ 1 may be produced as follows: mice obtained from RBF/DN mice may be immunized with about 100 ⁇ l of packed T lymphocytes; their spleens may subsequently e removed and fused with myeloma cells, for example, NS-1/FOX-NY myeloma cells, as described by Oi and Herzenberg (1980, in "Selected Methods In Cellular Immunology," Mishell and Shiigi, eds, Freeman and Co., San Francisco, pp. 351-373) and Taggart and Samloff (1983, Science 219:1228-1230).
  • Viable heterokaryons may then be selected in RPM1 1640 media supplemented with adenine/aminopterin/thymidine.
  • Hybridomas producing antibody directed toward lymphocyte ECMRs may be screened by adhesion to fibronectin-coated surfaces and cloned by limiting dilution.
  • antibodies directed toward ⁇ 4 ⁇ 1 may be identified, for example, by the ability to block adherence of lymphocytes to substrate coated with CS-1 peptide or its derivatives, or to endothelial cells.
  • Antibodies which recognize ⁇ 4 ⁇ 1 will not, however, inhibit the binding of cells bearing the ⁇ 5 ⁇ 1 receptor to RGD- peptide coated substrate.
  • antibodies directed toward ⁇ 4 ⁇ may be identified by their ability to i) competitively inhibit the binding of known anti- ⁇ 4 ⁇ 1, antibodies (such as P4C2 or P4C10), or ii) bind to the same protein as known anti- ⁇ 4 ⁇ 1, antibodies (e.g. in a protein gel, Western blot, or in sequential immunoprecipitation experiments).
  • the interaction between an extracellular membrane receptor may be characterized, for example, and not by way of limitation, by the following methods:
  • receptor distribution may be determined using any method known in the art.
  • cell populations bearing the ECMR may be identified using monoclonal antibodies directed toward the ECMR of interest. Binding of antibody to the ECMR may be detected using immunohistochemical techniques such as immunofluorescence and immune peroxidase staining. Alternatively, populations of cells bearing the ECMR of interest may be collected using fluorescence- activated cell sorting techniques.
  • one method for characterizing the functional interaction between a given receptor and a potential ligand involves determining whether the ECMR of interest distributes into the focal adhesions formed between cell and ligand substrate. For example, and not by way of limitation, ⁇ 4 ⁇ 1 may be shown to interact with fibronectin in a receptor/ligand relationship by the following method (see also section 6.2.3., infra).
  • Lymphocytes may be allowed to adhere to a fibronectin substrate, and the focal adhesions between cells and substrate may be visualized by interference reflexion microscopy (Izzard et al., 1976, J. Cell Sci. 21:129-159).
  • Antibodies which recognize ⁇ 4 ⁇ 1, such as P4G9 or P4C10, may be used to show, using standard immunohistochemical techniques, e.g. fiuoro-iso thiocyanate, that in the absence of serum, ⁇ 4 ⁇ 1 redistributes into the focal adhesions.
  • Interaction between ECMR and ligand may also be characterized by testing for the ability of the ECMR to adhere to a variety of different substrates.
  • a cell type of interest or an ECMR of interest may be tested for the ability to bind to substrates consisting of purified components of the extracellular matrix, such as fibronectin, collagen, vitronectin or laminin.
  • substrates consisting of purified components of the extracellular matrix, such as fibronectin, collagen, vitronectin or laminin.
  • cells bearing the ⁇ 4 ⁇ 1 may be shown to adhere to fibronectin, but not to collagen or laminin substrates as a result of the ⁇ 4 ⁇ 1/fibronectin interaction.
  • substrates bearing subfragments of the protein ligand may be tested for the ability to bind to an ECMR on the surface of cells, thereby permitting the localization of the binding site between ECMR and ligand.
  • the receptor is ⁇ 4 ⁇ 1
  • substrates bearing subfragments of fibronectin may be tested for their ability to bind ⁇ 4 ⁇ 1-bearing cells, as exemplified in Section 6, infra.
  • T lymphocytes attached to the 80 kDa cell binding domain of fibronectin bearing the ⁇ 4 ⁇ 1, receptor demonstrated a clear preference for an non-RGD containing region located on a 38 kDa tryptic fragment derived from the A (or heavy) chain of plasma fibronectin.
  • T lymphocytes also recognized and bound to another Hep II containing 58 kDa fragment.
  • the high affinity lymphocyte binding site was located on the 38 kDa fragment.
  • the 38 kDa fragment was three times more efficient than the 58 kDa fragment in mediating T lymphocyte adhesion.
  • the 38 kDa and 58 kDa fragments were derived from the A and B chains of plasma fibronectin, respectively. They therefore differ in the presence or absence of IIICS (Komblihtt et al., 1985, supra; Garcia-Pardo, 1987, supra).
  • IIICS IIICS
  • the 38 kDa and 58 kDa fragments used here share a common low affinity T lymphocyte binding site, located in the Hep II domain, and that additional high affinity T lymphocyte adhesion sites are present in the IIICS region unique to the 38 kDa fragment.
  • T lymphocytes appear to specifically recognize and bind to CS-1, which has been defined as a high affinity adhesion site for B16 melanoma cells and avian neural crest cells (Humphries et al., 1987, supra: Humphries et al., 1988, J. Cell Biol., 106:1289-1297; Dufour et al., 1988, EMBO J., 7:2661-2671).
  • CS-1 is a region of molecular heterogeneity (generated by alternative splicing) present in the type III CS domain on the A chain of plasma fibronectin. 5.2.2. Intervention In Receptor/Ligand Binding
  • the ECMR/ligand relationship may be further characterized by identifying and evaluating agents which interfere with receptor/ligand binding.
  • antibodies directed to an ECMR of interest may be used to inhibit ligand/receptor binding. Given the observation that a particular cell type adheres to a given ligand or cellular substrate, it may be of interest to identify the ECMR involved in the interaction. A panel of monoclonal antibodies, each directed toward a different ECMR, may be tested for the ability to block the adherence of cells to substrate. Inhibition of binding by a particular antibody would suggest that the ECMR recognized by that antibody is involved in the adhesive interaction.
  • lymphocyte adherence to endothelial cells in culture may be inhibited by antibodies directed toward ⁇ 4 ⁇ 1, but not by antibodies directed toward a variety of other ECMRs (see Section 7, below), indicating that ⁇ 4 ⁇ 1, is necessary for lymphocyte adhesion to endothelial cells.
  • monoclonal antibodies may be used to determine the relationship between ECMR and ligand substrate.
  • T lymphocyte adhesion to the 38 and 58 kDa fragments could be completely inhibited by functionally defined monoclonal antibodies to ⁇ 4 ⁇ 1.
  • T lymphocyte adhesion to CS-1 (IgG conjugate) coated surfaces could also be completely inhibited by P4C2, P3E3 or P4G9.
  • ⁇ 4 ⁇ 1 is the T lymphocyte receptor for CS-1.
  • these antibodies failed to inhibit adhesion of T cells to the 80 kDa fragment containing the prototype adhesion sequence arg-gly-asp (RGD).
  • Adhesion of T cells to the 80 kDa fragment could be completely inhibited by a monoclonal antibody to ⁇ 5 ⁇ 1 (P1D6) or by RGDS.
  • P1D6 and RGDS failed to inhibit T lymphocyte adhesion to the 38 and 58 kDa fragments or to CS-1.
  • ⁇ 4 ⁇ 1 functions as the receptor for the carboxy terminal adhesion domain of plasma fibronectin receptor for alternative adhesion sequences in IIICS (CS-1) and possibly Hep II.
  • the ECMR/ligand relationship may be characterized by determining the structure of the ligand.
  • the ability of agents to compete with ligand in the ECMR/ligand interaction may be evaluated.
  • the ligand is a protein
  • various fragments of the protein may be tested for their ability to competitively inhibit receptor/ligand binding.
  • peptide fragments of fibronectin may be tested for the ability to competitively inhibit the binding of lymphocytes to endothelial cell substrate.
  • CS-1 peptide and, in particular, the peptide EILDVPST was able to competitively inhibit the binding of lymphocytes to fibronectin and to endothelial cells, thereby localizing the binding site on the ligand to a region identical or homologous to EILDVPST.
  • adherence of one cell to another may be inhibited by intervening in the ECMR/ligand interaction.
  • the binding of lymphocytes to endothelial cells may be inhibited by interfering with the binding of ⁇ 4 ⁇ 1 to its ligand. This may be accomplished by using antibodies directed toward the ECMR, or, alternatively, to its ligand (antibodies may be generated toward ligand in a manner analogous to that described in Section 5.1).
  • peptides which inhibit the binding of ⁇ 4 ⁇ 1 to its ligand may be used to, in turn, inhibit adherence of lymphocytes to endothelial cells.
  • anti- ⁇ 4 ⁇ 1 antibody may be used to inhibit the binding of lymphocytes bearing ⁇ 4 ⁇ 1 receptors to vascular endothelial cells.
  • the antibody is a monoclonal antibody, in particular antibody P4C2 ( ⁇ 4 ⁇ 1) or P4C10 ( ⁇ 1), or fragments or derivatives thereof, including chimeric antibodies with the same binding specificities.
  • peptides may be used to inhibit the binding of lymphocytes bearing ⁇ 4 ⁇ 1 receptors to vascular endothelial cells.
  • the peptide comprises at least a portion of the sequence of the IIICS variable region of fibronectin.
  • the peptide comprises at least a portion of the CS-1 peptide as defined by Humphries et al., (1987, J. Biol. Chem. 262:6886-6892), which is incorporated by reference in its entirety herein, or a peptide substantially homologous to it.
  • the peptide comprises at least a portion of the sequence EILDVPST, or a sequence substantially homologous thereto.
  • the adherence of one cell to another may be inhibited by interfering in the binding between the ECMR and its ligand.
  • the adherence of lymphocytes to endothelial cells may be inhibited by interfering with the binding of ⁇ 4 ⁇ 1 on lymphocytes to its ligand on the endothelial cell surface.
  • the interaction of additional ECMR with endothelial cell ligands, and the inhibition of adhesion of these cells to endothelium by interfering with the ECMR/endothelial cell interaction is envisioned.
  • the adhesion of macrophages to the endothelium may also be inhibited by intervention in the macrophage ECMR/endothelial cell interaction.
  • melanoma cells which also recognize the CS-1 peptide, may be inhibited from metastasizing and entering tissues using the peptides or antibodies of the invention.
  • the present invention provides for a method of suppressing the immune response in human patients in need of such treatment.
  • the present invention provides for methods of treatment of diseases associated with chronic or relapsing activation of the immune system, including collagen vascular diseases and other autoimmune diseases (such as systemic lupus erythematosis and rheumatoid arthritis), multiple sclerosis, asthma, and allergy, to name but a few.
  • the present invention also provides for methods of treatment of relatively acute activations of the immune system in patients in need of such treatment, including, for example, and not by way of limitation, graft versus host disease, allograft rejection, or transfusion reaction.
  • lymphocyte migration into tissues systemically or, alternatively, locally it may be desirable to inhibit lymphocyte migration into tissues systemically or, alternatively, locally.
  • tissue systemically in diseases involving multiple organ systems, such as systemic lupus erythematosis, it may be desirable to inhibit lymphocyte adhesion systemically during a clinical exacerbation.
  • lymphocyte adhesion in diseases involving multiple organ systems, such as systemic lupus erythematosis, it may be desirable to inhibit lymphocyte adhesion systemically during a clinical exacerbation.
  • lymphocyte adhesion systemically during a clinical exacerbation.
  • Control of systemic versus localized use of the methods of the present invention may be achieved by modifying the compositions of antibodies or peptides administered or by altering the structure of these agents or their pharmacologic compositions.
  • the antibodies or peptides of the invention may be administered by any route, including subcutaneous, intramuscular, intravascular, intravenous, intraarterial, intranasal, oral, intraperitoneal, rectal, intratracheal, or intrathecal.
  • a suitable pharmacologic carrier subcutaneously or intramuscularly.
  • a pharmacologic carrier which facilities delivery of the antibodies, peptides, etc. of the invention.
  • a pharmacologic carrier which aids in the penetration of the cuticle, epidermis, and dermis may be advantageous.
  • Dissemination of the peptides or antibodies of the invention may also be controlled by altering the half-life of the peptide or antibody, or its effective half- life.
  • the peptides of the invention may have a relatively short half life; if these peptides were administered in a sustained release implant, the area of tissue adjacent to the implant would be exposed to peptide, (e.g. a joint in a rheumatoid arthritis patient) whereas the peptide may be degraded before reaching more distant tissues.
  • the peptide is modified to achieve a longer half-life by chemical modifications to produce derivatives, including but not limited to amino acid substitutions, glycosylations, substitution of enantiomeric variants (i.e. D-enantiomers of constituent amino acids), additions, etc., the peptide is more likely to be widely distributed at sustained levels.
  • the N-terminus or C-terminus of the peptides may be modified to result in greater stability.
  • the antibodies or peptides of the invention may be conjugated to antibodies or other ligands which might direct the antibodies or peptides to specific tissues.
  • peptides of the invention may be conjugated to antibodies targeted toward endothelial cells.
  • antibodies may be produced which mimic the ECMR, and thereby attach to endothelial cell ligands, blocking lymphocyte adhesion.
  • the peptides of the invention include any peptide which is capable of interacting with the ECMR of interest.
  • any peptide which is capable of interacting with the ⁇ 4 ⁇ 1 receptor may be used to inhibit the binding of lymphocytes to endothelium.
  • these peptides may be shown to inhibit adhesion of lymphocytes to endothelium in vitro prior to in vivo use.
  • the peptides comprise at least a portion of the fibronectin IIICS region.
  • the peptides comprise at least a portion of the CS-1 peptide sequence, or a sequence substantially homologous to the CS-1 sequence as presented in FIGURE 9(a) and (b).
  • the peptides of the invention comprise at least a portion of the sequence EILDVPST or a peptide sequence substantially homologous thereto. "Substantially homologous" should be construed to mean that the peptides of the invention may be alterations of the specified sequence such that a functionally equivalent amino acid is substituted for one or more amino acids in the peptide sequence, thus producing a silent change.
  • one or more amino acid residues within the sequence can be substituted by another amino acid of a similar polarity which acts as a functional equivalent.
  • Substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs.
  • the non- polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine.
  • the polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.
  • the positively charged (basic) amino acids include arginine, lysine, and histidine.
  • the negatively charged (acidic) amino acids include aspartic and glutamic acid.
  • the present invention also relates to derivatives of the above-mentioned peptides.
  • Antibodies of the invention include monoclonal as well as polyclonal antibodies and fragments and derivatives thereof, including the F(ab') 2 , Fab', and Fab fragments.
  • Fluorescein-conjugated (goat) anti-mouse IgG and IgM (H and L chains) or rhodamine-conjugated (goat) anti-rabbit IgG and IgM (H and L chains) were obtained from Tago, Inc. (Burlingame, CA).
  • R-phycoerythrin-conjugated strepavidin was from Biomeda (Foster City, CA).
  • Rabbit anti-mouse IgG (H+L) antiserum was obtained from Cappel (Cooper Biomedical, Malvem, PA). 5 1 Cr-sodium chromate was from New England Nuclear.
  • 125 I was from Amersham (Arlington Hts., IL).
  • IL-2 Human recombinant interleukin-2 (IL-2) was a generous gift from Dr. D. Urdal (Immunex Corp., Seattle, WA). Laminin was purchased from Collaborative Research, Inc. Bedford, MA) and purified plasma fibronectin and collagen Types I and III were prepared as previously described (Wayner, E. A. and Carter, W. G., 1987, supra and Wayner et al., 1988, supra).
  • RD Human rhabdomyosarcoma
  • HT1080 human fibrosarcoma
  • PBMC Peripheral blood mononuclear cell
  • platelet and granulocyte populations from normal human donors were prepared as described (Kunicki et al., 1988, supra; Wayner et al., 1988, supra).
  • Peripheral blood cells from patients with acute lymphocytic, large granular lymphocyte (LGL) or myelogenous leukemia were obtained from Dr. I. Bernstein and Dr. T. Loughran (Fred Hutchinson Cancer Research Center).
  • Human lymphokine 500 U/ml IL-2) activated killer (LAK) cells and the monoclonal HLA B7 specific human cytotoxic T lymphocyte (CTL) cell line, C1C4, were prepared according to standard protocols (Grimm et al., 1982, J. Exp. Med., 155:1923-1941; Glasebrook, A. L. and Fitch, F. W., 1980, J. Exp. Med., 151:876-895; Brooks, 1983, Nature, 305:155-158; Wayner, E. A. and Brooks, C. G., 1984, J. Immunol., 132:2135-2142; Wayner, E. A. and Carter, W. G., 1987, J.
  • the EBV transformed B lymphocyte cell line (BLCL), ST-1, was derived from the donor spleen used in the production of the C1C4 CTL line. All other cell lines and cell culture conditions were as previously described (Wayner, E. A. and Carter, W. G., 1987, supra: Wayner et al., 1988, supra). 6.1.3. Antibodies
  • P1B5 Monoclonal antibodies to the integrin receptors ⁇ 3 ⁇ 1 (P1B5), ⁇ 2 ⁇ 1 (P1H5) and ⁇ 5 ⁇ 1 (P1D6) have been described and were developed in this laboratory.
  • P1H5 and P1D6 inhibit fibroblast and platelet adhesion to collagen and fibronectin-coated substrates, respectively (Wayner, E. A. and Carter, W. G., 1987, supra: Kunicki et al., 1988, supra; Wayner et al., 1988, supra).
  • Monoclonal antibodies to lymphocyte adhesion receptors were produced by the methods of Oi and Herzenberg (Oi, V.T. and Herzenberg, L.A. 1980, Immunoglobulin producing hybrid cell lines. In: Selected Methods in Cellular Immunology. Ed. by B.B. Mishell and S.M. Shugi. W.H. Freeman and Co.. San Francisco, pp. 351-373) and Taggart and Samloff (Taggart, R.T. and Samloff, I.M., 1983, Science, 219, 1228-1230) as described (Wayner and Carter, 1987;
  • A1A5 (Hemler et al., 1987, J. Biol. Chem. 262:3300-3309) reacts specifically with the ⁇ 1 subunit of the integrin receptors, and has been reported to inhibit cell adhesion, Takeda et al. (1988, J. Cell. Biochem.
  • P4C10 a functionally defined anti- ⁇ 1 monoclonal antibody, P4C10, was produced using the previously described techniques (supra) and by screening inhibition of cell adhesion to multiple ligands. P4C10 has been shown to inhibit adhesion of cells to fibronectin, CS-1, collagen and laminin coated surfaces and reacts with ⁇ 1 by standard biochemical criterion. 6.1.4. Inhibition Of Cell Adhesion To Intact Fibronectin And
  • Antibodies that would alter cell adhesion to purified plasma fibronectin, tryptic fragments and CS peptides were identified as previously described (Wayner and Carter, 1987). Briefly, 48 well virgin styrene plates were coated with human plasma fibronectin (5 ⁇ l/ml). The plates were blocked with PBS supplemented with 10 mg/ml heat denatured BSA (HBSA).
  • HBSA heat denatured BSA
  • T lymphocyte or HT1080 cells were labeled with Na 2 51 CrO 4 (50 ⁇ lCi/ml for 2-4 hr), washed, and 5 X 10 4 HT1080 or cultured T cells or 5 X 10 10 PBL/well were incubated with hybridoma culture supematants (1:2 dilution in PBS supplemented with 1 mg/ml heat denatured BSA) or control myeloma cell culture supernatant for 15 minutes at room temperature. The cells were allowed to adhere to the protein-coated surfaces in the presence of the hybridoma supematants for 15-30 minutes (HT1080) or 2-4 hours (lymphocytes) at 37°C. Non-adherent cells were removed by washing with PBS, and the adherent cells were dissolved in SDS/NaOH and bound 51 Cr-cpm were quantitated in a gamma counter.
  • Viable cells were surface labeled with 125-iodine as described (Wayner and
  • TPCK-trypsin for 90 min at 37°C, and the digest was fractionated by affinity and ion-exchange chromatography as previously described (Garcia-Pardo et al., 1987, Biochem. J. 241:923-928; Garcia-Pardo et al., 1989, Exp. Cell Res. 181:426-431).
  • Two overlapping peptides spanning the initial 48 residues of the IIICS region of human fibronectin (CS-1 and CS-2) were synthesized and coupled to rabbit IgG as described (Humphries et al., 1986, and Humphries et al., 1987, J. Biol. Chem. 262:6886-6892).
  • 10 6 cells in suspension were incubated for 30 minutes with protein G-Sepharose purified goat IgG (20 ⁇ g/ml) and then with first stage antibodies at 4°C for 60 minutes, washed in Hanks Balanced Salt solution containing 10 mg/ml HBSA and 0.02% sodium azide (Hanks/BSA/SA) and incubated with FITC-conjugated rabbit anti-mouse IgG for 60 minutes at 4°C in Hanks/BSA/SA. They were washed and fixed in cold 2% paraformaldehyde (prepared fresh) in PBS.
  • Adherent cells were trypsinized, washed in RPMI supplemented with 1 ⁇ g/ml BSA plus 100 ug/ml soybean trypsin inhibitor and allowed to adhere to acid washed and silanized glass cover slips coated with fibronectin, laminin or collagen (20 ug/ml) in the absence of serum for 1-4 hour as described (Carter and Wayner, in preparation). At the end of the incubation non-adherent cells were removed and adherent cells were fixed in 100 mM sodium cacodylate, 100 mM sucrose, 4.5 mM CaCl 2 , 2% formaldehyde for 20 min.
  • Cryostat sections (6 ⁇ m) were prepared from human skin, tonsil, or tumor samples embedded in OCT medium after snap freezing in isopentane/liquid nitrogen. All sections were fixed in 4% paraformaldehyde in PBS prior to incubation with primary antibodies and secondary fluorescent antibodies as described (Carter and Wayner, 1988, J. Biol. Chem. 263:4193-4201). In control experiments, no fluorescence of rhodamine was detected using the fluorescein filters or vice versa.
  • p150 The biochemical characteristics of p150 suggested that it might be related to the VLA 4 antigen described by Hemler (Hemler et al., 1987). This was confirmed by sequential immune precipitation (not shown) with a VLA 4 specific monoclonal antibody, B5-G10. p150 was established as an a subunit of the integrin super famlly by its association with ⁇ 1 when immune precipitations were carried out after CHAPS detergent (0.3%) solubilization of 125 I surface labeled T lymphocytes in the presence of 1 mM Ca ++ (FIGURE 3). Under these conditions ⁇ 4 was precipitated as a heterodimer with ⁇ 1. The identity of ⁇ 1 was confirmed by V8 protease peptide mapping (not shown).
  • the ⁇ 4 ⁇ 1 heterodimer immune precipitated from T lymphocytes with the inhibitory monoclonal antibodies (P3E3, P4C2 and P4G9) was shown to be distinct from the prototype fibronectin receptor, ⁇ 5 ⁇ 1, immune precipitated with P1D6 by three criteria.
  • the relative quantities of ⁇ 4 ⁇ 1 and ⁇ 5 ⁇ 1 present in detergent extracts of T lymphocytes were distinct with higher levels of ⁇ 4 ⁇ 1 being present (FIGURE 3). This was in agreement with the data we obtained using flow cytometry (FIGURE 1).
  • monoclonal antibodies to ⁇ 4 ⁇ 1 did not preclear ⁇ 5 ⁇ 1 (now shown).
  • V8 protease peptide maps derived from the ⁇ 4 and ⁇ 5 subunits precipitated with monoclonal antibodies P3E3 and P1D6 were clearly distinguishable (not shown). Furthermore, under the conditions (0.3% CHAPS and ImM CaCl 2 ) used to solubilize the conjugate of ⁇ 4 ⁇ 1 from Jurkat cells (FIGURE 3) another protein of higher molecular weight (p180) also reacted with the monoclonal antibodies or co-precipitated with ⁇ 4 ⁇ 1. pi 80 was absent from extracts prepared with P1D6 monoclonal antibody (FIGURE 3), non-lymphoid cells or Triton X-100 detergent extracts prepared in the absence of Ca ++ .
  • lymphocyte subpopulations derived from spleen, tonsil and peripheral blood expressed abundant a4b1.
  • peripheral blood monocytes, freshly derived acute lymphocytic (T or B) leukemias, all large granular lymphocytic (LGL) and myelogenous leukemias and cultured T and B lymphocyte cell lines we examined expressed abundant a4b1 (Table IV). Normal human blood platelets and granulocytes were negative for a4b1 (Table IV). Normal human blood platelets and granulocytes were negative for a4b1.
  • T cells hematopoietic cell populations that expressed ⁇ 5 ⁇ 1 were activated T cells, platelets, monocytes and granulocytes, acute lymphocytic (T or B) and myelogenous leukemias and cultured K562, HL-60 and U937 cells.
  • Some cultured T (Molt 4 or Jurkat) and B (ST-1) cell lines expressed low levels of ⁇ 5 ⁇ 1 as detected by P1D6 monoclonal antibody.
  • P1D6 monoclonal antibody a subpopulation of PBL were positive for P1D6 fluorescence detected by flow cytometry. We are investigating the nature of this subpopulation of PBL which express ⁇ 5 ⁇ 1.
  • TY cells a CD3 T cell lymphoma, were completely negative for P1D6 by flow cytometry.
  • the major fibronectin receptor constitutively expressed by resting T lymphocytes is ⁇ 4 ⁇ 1 and as we have previously reported (Wayner et al., 1988) expression of ⁇ 5 ⁇ 1 in T lymphocytes is restricted to leukemic or activated cultured cells.
  • most fibroblast cell lines expressed low levels of ⁇ 4 ⁇ 1 whEe large vessel endothelial cells (HUVEs) and cultured epithelial cells were negative for ⁇ 4 ⁇ 1 by flow cytometry.
  • HUVEs large vessel endothelial cells
  • ⁇ 4 ⁇ 1 was present in adult spleen, lymph node and tonsil and essentially absent from all other tissues we examined.
  • the relative quantities of the fibronectin adhesion receptors expressed by cells in specific tissue domains varied dramatically .
  • PBL and lymphocytes in tonsil and cortex and germinal center areas expressed large quantities of ⁇ 4 ⁇ 1 but virtually no ⁇ 5 ⁇ 1.
  • ⁇ 4 ⁇ 1 was also found in epithelial regions in adult lymphatic tissue, but whether this was the result of lymphocyte infiltration of these areas or expression of ⁇ 4 ⁇ 1 by lymphatic epithelial cells was unclear.
  • FIGURE 4B arrows
  • FIG. 4D staining with monoclonal antibody P4G9
  • FIG. 4D shows that ⁇ 4 ⁇ 1 was also concentrated in focal adhesions when cells were grown on fibronectin but not Iamimn-coated surfaces (not shown).
  • FIGURE 5A and B To determine the region of fibronectin that interacts with ⁇ 4 ⁇ 1 we examined the adhesion of cultured T lymphocytes to various proteolytic fragments of plasma fibronectin (see FIGURE 5A and B), as well as the effect of monoclonal antibodies P1D6 and P4C2 on lymphocyte adhesion to these fragments.
  • FIGURE 6 Jurkat, YT and Molt 4 cells attach to a 38 kDa fragment containing the Heparin (Hep) II domain much more efficiently than to an RGD-containing fragment (80 kDa).
  • Jurkat and Molt 4 cells also attach m a dose dependent manner to another Hep E domain containing fragment of 58 kDa.
  • hematopoietic cell lines such as K562 cells (FIGURE 6) exhibited a clear preference for the 80 kDa fragment of plasma fibronectin while RD cells expressed promiscuous adhesion to all the fragments of plasma fibronectin tested except the N-terminal 29 kDa fragment.
  • RDGS (1 mg/ml) partially inhibited (50%) Jurkat cell adhesion to mtact fibronectin and completely (100%) inhibited their adhesion to the 80 kDa fragment.
  • Jurkat cell adhesion to the 38 kDa fragment was unaffected by RGDS (up to 1 mg/ml).
  • T lymphocytes to the 58 kDa fragment which also contains Hep II could be inhibited by P4C2.
  • T lymphocyte cell lines which express both ⁇ 4 ⁇ 1 and ⁇ 5 ⁇ 1 (such as Jurkat cells) behave exactly as Molt 4 cells (FIGURE 7).
  • K562 cells express only ⁇ 5 ⁇ 1.
  • Adhesion of K562 cells to the 38 (FIGURE 6) and 58 kDa fragments was greatly reduced when compared to their adhesion to the 80 kDa fragment (FIGURE 6).
  • Adhesion of these cells to intact plasma fibronectin (FIGURE 1) or the 80 kDa fragment could be completely inhibited by P1D6.
  • YT cells which do not express ⁇ 5 ⁇ 1 adhere poorly to intact plasma fibronectin and the 80 kDa fragment (FIGURE 6). These cells require 2-3 times longer to adhere to plasma fibronectin-coated surfaces than Jurkat or Molt 4 cells. YT cells, however, adhere efficiently and in a dose dependent manner to the 38 kDa fragment (FIGURE 6) and adhesion of these cells to the 38 kDa fragment could be completely inhibited by P4C2.
  • the IIICS region present on the A chain of plasma fibronectin contains at least two sites responsible for mediating cell adhesion to fibronectin (Humphries et al., 1986, J. Cell Biol. 103: 2637-2647; Humphries et al. ; 1987, J. Biol. Chem. 262:8886-6892; Humphries et al.; 1988, J. Cell Biol. 106:1289-1297).
  • CS peptides Humphries and co-workers showed that the CS-1 (N-terminal) peptides contained adhesion sequences recognized by mouse melanoma cells (Humphries et al., 1986, 1987).
  • 38 kDa fragment contains a high affinity adhesion site recognized by human T lymphocytes and that ⁇ 4 ⁇ 1 is the receptor which mediates T lymphocyte adhesion to 38 kDa. This fragment does not contain the CS-5 site but it does contain the entire CS-1 region (Garcia-Pardo et al., 1987, Biochem.
  • T lymphocytes (Jurkat or Molt 4 cells) recognize and attach to CS-1 (rabbit IgG conjugate) -coated plastic surfaces (Table VI).
  • T lymphocytes (Jurkat) do not attach to CS-2 (rabbit IgG conjugate) coated surfaces or to plastic surfaces coated with rabbit IgG alone.
  • monoclonal antibodies to ⁇ 4 ⁇ 1 (P4C2) completely inhibited T lymphocyte adhesion to CS-1 while antibodies to ⁇ 5 ⁇ 1 (P1D6) had absolutely no effect (Table VI).
  • the ligand in IIICS for ⁇ 4 ⁇ 1 was the CS-1 region previously defined as an adhesion site for melanoma cells.
  • the functionally defined monoclonal antibodies to ⁇ 4 partially inhibited T lymphocyte adhesion to intact plasma fibronectin and had no effect on their attachment to an 80 kDa tryptic fragment containing the RGD adhesion sequence.
  • Monoclonal antibodies (P1D6 and P1F8) to the previously described fibronectin receptor, cc5 ⁇ 1 completely inhibited T lymphocyte adhesion to the 80 kDa fragment but had no effect on their attachment to the 38 kDa fragment or to CS-1.
  • Both ⁇ 4 ⁇ 1 and ⁇ 5 ⁇ 1 localized to focal adhesions when fibroblasts which express these receptors were grown on fibronectin-coated surfaces.
  • Liao et al., 1989, Exp. Cell Res., 181:348-361 reported that someB lymphocyte cell lines bind to a region of plasma fibronectin located within the carboxy terminal Hep II domain. Liao et al., 1987, supra identified an integrin- like receptor on B cells. However, it is not clear whether the protein they described was ⁇ 4 ⁇ 1, ⁇ 2 ⁇ 1 or ⁇ 5 ⁇ 1. Behap et al., 1987, supra also identified fibronectin receptors expressed by B lymphocytes.
  • the 38 kDa fragment does not contain CS-5 (Garcia-Pardo, 1987, supra) the minimal amino acid sequence responsible for T lymphocyte adhesion to 38 kDa and therefore the ligand for ⁇ 4 ⁇ 1 in these cells is not arg-gluasp-val or REDV (Humphries et al., 1986, supra).
  • LAK cells expressed abundant cell surface ⁇ 4 ⁇ 1 it did not appear to be a functional receptor; P1D6 completely inhibited LAK cell adhesion to fibronectin. The reason for this could be that LAK cells express a degraded form of ⁇ 4 (see FIGURE 2). In addition, because they are activated, LAK cells over express ⁇ 5 ⁇ 1 when compared to resting peripheral blood or leukemic T cells (Table VIII). In other cells which express larger quantities of ⁇ 5 ⁇ 1 relative to ⁇ 4 ⁇ 1 (K562-1 and HT1080) adhesion to the 80 kDa RGD containing domain via ⁇ 5 ⁇ 1 is dominant (see K562-1 cells, FIGURE 6).
  • T lymphocytes use two independent receptors during attachment to fibronectin and that i) ⁇ 5 ⁇ 1 is the receptor for the RGD containing cell adhesion domain, and ii) ⁇ 4 ⁇ 1 is the receptor for a carboxy terminal cell adhesion region containing the Heparin E and EICS domains. Furthermore, these data show that T lymphocytes express a clear preference for a region of molecular heterogeneity in IIICS (CS-1) generated by alternative splicing of fibronectin pre-mRNA and that ⁇ 4 ⁇ 1 is the receptor for this adhesion site.
  • CS-1 molecular heterogeneity in IIICS
  • cytokines associated with the inflammatory response including IL-1, tumor necrosis factor alpha (TNF ⁇ ), and tumor necrosis factor beta (TNF ⁇ ).
  • TNF ⁇ tumor necrosis factor alpha
  • TNF ⁇ tumor necrosis factor beta
  • Jurkat Human T cell leukemia
  • Dr. Paul Conlon Immunex. Corp., Seattle, WA
  • Ramos Human B cell Leukemia
  • the LAD (leukocyte adhesion deficient) and ST-1 B cell lines were prepared by Epsten-Barr virus transformation of human B lymphocytes.
  • the LAD cell line was developed from the B cells of a patient with a deficiency in the ⁇ 2 integrin family of adhesion receptors and was obtained from Dr. John Harlan (Harborview Medical Center, Seattle, WA).
  • Human umbilical vein endothelial cells (HUVEs) were purchased from Cell Systems, Seattle, WA.
  • HUVEs were maintained in defined (serum-free) media also purchased from Cell Systems (CS-100 media).
  • HUVEs were incubated with IL-1 ⁇ (1 ng/ml) or in some experiments with TNF ⁇ (10 ng/ml) for 6-24 hours. At the end of this incubation the HUVE monolayers were washed and used in the adhesion assay.
  • Peptides derived from the CS-1 region of plasma fibronectin were synthesized and HPLC purified according to standard protocols by Dr. James Blake at the Oncogen Corp., Seattle, WA.
  • the CS-1 peptide was conjugated to rabbit serum albumin or KLH also according to standard protocols by Dr. James Blake.
  • the RGDS control peptide was obtained from Peninsula Laboratories (Belmont, CA).
  • P1H5 which recognizes the ⁇ 2 ⁇ 1 receptor (Wayner et al., 1987, J. Cell Biol. 105:1873-11884; Wayner et al. 1988, J. Cell Biol. 107:1881-1891); P1B5, which recognizes the ⁇ 3 ⁇ 1 receptor (supra): P1D6, which recognizes the ⁇ 5 ⁇ 1 prototype fibronectin receptor described by Pytela et al. (Cell 40:191-198); P4C10, which recognizes the ⁇ 1 subunit; and P4H9 which recognizes ⁇ 2 (CD18), using methods described fully in Wayner et al. (1987, J. Cell Biol. 105:1873-1884) and Wayner et al. 1988, J. Cell. Biol. 107:1881-1891) which are incorporated in their entirety by reference herein, and described in Table II.
  • HUVEs Human umbilical vein endothelial cells
  • lymphocytes were labeled with Na 2 51 CrO 4 (50 ⁇ Ci/ml) for 2-4 hours), washed, and then 10 5 lymphocytes were incubated with HUVE monolayers in the presence or absence of inhibitory antibodies or CS-1 derived peptides. The lymphocytes were allowed to adhere for 30 minutes at 37°. Non- adherent cells were subsequently removed by washing with PBS, and the adherent cells were dissolved in SDS/NaOH. Bound 51 Cr-cpm were quantitated in a gamma counter.
  • endothelial cells were activated prior to the adhesion assay by incubating with IL-1 ⁇ (1 ng/ml) or TNF- ⁇ (10 ng/ml) for 6-24 hours in defined CS-100 media (Cell Systems, Seattle, WA).
  • lymphocytes use during extravasation we first determined the surface phenotype of normal and LAD lymphocytes with respect to the integrin receptors. These data are in Table VII and show clearly that the LAD cells possess a normal cell surface phenotype with respect to the ⁇ 1 containing integrins. Since, as expected, the B cells derived from the patient with LAD were negative for ⁇ 2, this strongly suggests that LAD lymphocytes use the ⁇ 1 contaimng integrins during their adhesion to and passage through the endothelium.
  • Chromium-labeled lymphocytes from various cell lines were tested for theirability to adhere to either resting or activated endothelial cells (Table VII). Although all the cell lines tested were found to adhere to some extent to resting endothelium, adhesion of T and B lymphocytes to endothelium activated by either IL-1 or TNF was observed to be much greater, by a factor of as much as ten-fold. Adhesion of lymphocytes from LAD patients to endothelium was not found to be significantly different from that observed for ST-1 cell lines derived from normal B cells (ST-1). There was no difference observed among cell lines between adhesion to IL-1 versus TNF activated endothelium.
  • the ability of synthetic CS-1 and derivative peptides to inhibit adherence of chromium-labeled lymphocytes to activated endothelial cells was evaluated using various peptides.
  • the synthetic CS-1 peptide was a strong inhibitor of T or B lymphocyte adhesion to basal or activated endothelial cell monolayers (Tables X and XI).
  • the EILDVPST sequence was the minimal peptide also required to inhibit lymphocyte adhesion to resting or activated HUVEs (Tables X and XI). In some cases, such as with the Ramos B cell line, adhesion of these cells to HUVEs could be completely abrogated with the EILDVPST peptide.
  • the RGDS sequence which is the ligand for the prototype fibronectin receptor, ⁇ 5 ⁇ 1 , did not inhibit lymphocyte adhesion to resting or activated HUVEs.
  • LAD leukocyte adhesion deficiency
  • LFA-1, Mac-1 or p 150/95 ⁇ 2 containing receptors
  • lymphocytes do undergo diapedesis to pass through the endotheliumm and can be found in tissues derived from patients with this disorder. This, therefore, implies that lymphocytes use a mechanism distinct from the ⁇ 2 containing integrins during their passage from the blood stream into the peripheral tissues.
  • the following series of experiments comprises our attempts to fully understand the mechanisms utilized by peripheral blood lymphocytes during diapedesis.
  • lymphocyte cell lines tested were shown to express ⁇ 4 ⁇ 1 and/or ⁇ 5 ⁇ 1 by fluorescence analysis, and were observed to adhere to cultured human umbilical vein endothelial cells. This adhesion was found to be blocked only by monoclonal antibodies directed toward ⁇ 4 ⁇ 1 ; antibodies directed toward other receptors were not found to have essentially any inhibitory effect, revealing the importance of the ⁇ 4 ⁇ 1 receptor in the adhesive interaction between lymphocytes and endothelium.
  • synthetic CS-1 and derivative peptides (Tables 9, 10, and 11) were found to inhibit adhesion of lymphocytes to endothelium.
  • the amino acid sequence EILDVPST was found to be particularly important to the interaction.
  • lymphocyte ⁇ 4 ⁇ 1 receptor is, in fact, interacting with fibronectin on the endothelial cell surface. It is also possible that ⁇ 4 ⁇ 1 is recognizing the peptide EILDVPST or a similar sequence, in the context of another, non-fibronectin protein.
  • Minimal peptide and minimal peptide ligand are used herein interchangeably to mean a peptide of about 2 to about 12 amino acids in length, especially about 3 to about 8 amino acids in length, and most preferably about 3 to about 5 amino acids in length, wherein the peptide is either a) capable of inhibiting stable cell adhesion of one cell via a ⁇ 1-containing integrin receptor either to another cell or to a substrate containing an LDV amino acid sequence; or, b) capable of supporting stable cell adhesion to the substrate through the receptor when the peptide is coupled to a suitable carrier (e.g., rabbit serum albumin, RSA, or a liposome or antibody).
  • a suitable carrier e.g., rabbit serum albumin, RSA, or a liposome or antibody
  • Representative minimal peptides are provided by LDV, LDVPST, EEDV, LDVPST, GPEILDVPST, and LHGPEILDVPST, although those skilled in the art will recognize that various routine chemical modifications can be made (e.g., methylation, acylation, acetylation, sulfation, and the like) that will increase (or decrease) the binding affinity of the minimal peptide for the disclosed integrin receptors.
  • Antibodies to these functionally different receptors can be readlly raised, screened and selected pursuant to this disclosure.
  • Substrate surface coated with an LDV minimal peptide
  • LDV-coated surfaces and “coated styrene substrates” are used herein interchangeably to refer to minimal peptide ligands capable of binding to a ⁇ 1-containing integrin receptor on a cell surface such that the cell becomes stably adherent to the surface substrate.
  • Representative examples of surface substrates include LDVPST-RSA, EILDVPST-RSA, ED-DV-RSA, LDV-RSA, and protein substrates synthesized by cells (e.g., endothelial cells) that contain the LDV minimal peptide sequence. 8.1. Background
  • CTCBD carboxy terminal cell binding domain
  • the minimal peptide ligand in CS-1 that is capable of supporting stable hematopoietic cell adhesion via ⁇ 4 ⁇ 1 has been identified. Surprisingly, this ligand varied according to the cell population examined. Although the minimal peptide for melanoma cell adhesion was leu-asp-val (or LDV), many hematopoietic cell lines required larger portions of the C-terminal end of CS-1, while still other populations could be identified that required the entire length of CS-1 to form stable attachments. This suggests that the LDV sequence may be recognized by some cell populations only in the context of intact CS-1 and that the recognition may be regulated in a cell-type specific manner.
  • LDV leu-asp-val
  • LDV recognition is determined by the avidity of the ⁇ 4 ⁇ 1 complex expressed by an individual cell population.
  • a low avidity receptor expressed on Jurkat, Ramos, U937 or PHA activated T cells, does not bind LDV minimal peptides but does bind LDV in the context of CS-1.
  • a high avidity receptor expressed by HUT 78 or A375 melanoma cells, binds LDV-peptide coated surfaces.
  • the avidity of the low avidity ⁇ 4 ⁇ 1 receptor complex is altered by a monoclonal antibody (Mab) to ⁇ 1, 8A2. 8A2 was selected for itsability to promote ⁇ 4 ⁇ 1 dependent binding to fibronectin (Kovach, N.L., and J.M.
  • anti- ⁇ 1 antibodies suitable for increasing the avidity of a low avidity ⁇ 4 ⁇ 1 receptor complex include 4B4 (commerically available through Coulter Immunologies), and certain other antibodies to ⁇ 1 described by Springer (supra) and by others.
  • Suitability of a particular antibody for increasing the avidity of a low avidity ⁇ 4 ⁇ 1 receptor complex can be determined empirically by coating a surface with an LDV minimal peptide (e.g., an LDVPST-protein conjugate) and testing for the ability of the antibody to ⁇ 1 to increase the adherence of a suitable test cell (e.g., Jurkat, Ramos, a T lymphocyte PHA blast cell and the like) to the coated surface.
  • a suitable test cell e.g., Jurkat, Ramos, a T lymphocyte PHA blast cell and the like
  • Antibodies to ⁇ 1 that are not suitable for increasing avidity will either block binding of the test cell to the coated surface, or have no effect.
  • Surface expression of ⁇ 4 ⁇ 1 on cells treated with 8A2 remained unchanged (herein, see below). Therefore, in the presence of Mab 8A2 certain hematopoietic cells (e.g., Jurkat) could be induced to form stable attachments to LDV-coated surfaces. This suggests that recognition of the LDV sequence in CS-1 may requfre a change in the ⁇ 4 ⁇ 1 receptor complex that involves ⁇ 1.
  • PHA-stimulated, but not resting T cells could be induced by Mab 8A2 to bind LDV, suggesting that resting T cells require an additional signal(s) for LDV recognition.
  • hematopoetic cell mteractions with the carboxy terminal cell binding domain (CTCBD) of fibronectin may be regulated at least at the levels of: 1) ⁇ 4 ⁇ 1 expression; or, 2) activation of ⁇ 4 ⁇ 1; or, 3) the expression of the LDV minimal peptide in the CS-1 sequence of V+ fibronectin isoforms.
  • CTCBD carboxy terminal cell binding domain
  • Fibronectin was purified from human plasma as previously described (Wayner and Carter, 1987, J. Cell Biol. 105: 1873-1884). Fragments of fibronectin were the same as previously described (Wayner et al., 1989, supra; Garcia-Pardo et al., 1987, supra). 51 Cr-Sodium chromate was from New England Nuclear (Boston, MA). Rabbit serum albumin (RSA), bovine serum albumin (BSA) and Protein A-agarose were from Sigma Chemical Co. (St. Louis, MO). Protein G-agarose is commercially available (Pharmacia, La Jolla, CA).
  • peptides were synthesized with an N-terminal cysteine at the end of a gly-gly-gly tail and were chemically conjugated to SMCC-derivatized rabbit serum albumin (RSA) for use in cellular adhesion assays. None of the peptides, either inhibitory or non-inhibitory (or any of the peptide conjugates), were toxic or growth inhibitory.
  • RSA SMCC-derivatized rabbit serum albumin
  • the A375 (human melanoma) and the Jurkat (human T lymphoblastoid) cell lines are widely available (e.g., Jurkat cell line ATCC-CRL8163; A375 CRL 1619; American Type Culture Collection, Rockville, Maryland).
  • the HT1080, RD, Ramos, HSB-2 and HUT 78 cells were obtained from the American Type Culture Collection (Rockville, MD). All cell culture conditions were as previously described (Wayner and Carter, 1987, supra).
  • PHA stimulated T cell blasts were prepared as described from normal fresh human blood (Wayner et al., 1989, supra).
  • Monoclonal antibodies (Mabs) to adhesion receptors were produced and characterized as described (Wayner and Carter, 1987, supra; Wayner et al., 1988, J. Cell Biol. 107: 1881-1891; Wayner et al. , 1989, supra; Kovach, N.L ., and J.M. Harlan, personal communication).
  • the 8A2 Mab has been shown to recognize an epitope in the integrin ⁇ 1 subunit (Kovach, N.L. and J.M. Harlan, personal communication).
  • Anti- ⁇ 1, PAC10 that blocks cell adhesion is described herein (above), and in Wayner 1989, (supra).
  • the anti- ⁇ 4 Mab P4C2 has been previously described (Wayner et al., 1989, supra).
  • Control antibody consisted of Protein G purified non-immune mouse IgG.
  • the ⁇ 1 subunit was activated with Mab 8A2 in several ways.
  • cell adhesion assays were carried out in the presence of 8A2.
  • cells were pre-treated with 8A2 Mab for 30 min, washed and then used in cell adhesion assays.
  • the effects of 8A2 Mab could be measured with 10 min with as little as 0.1 ug/ml 8A2 being able to stimulate increased avidity of a low avidity ⁇ 4 ⁇ 1 receptor complex for fibronectin, CS-1, or LDV minimal peptides.
  • Antibodies that could alter adhesion of test cells to fibronectin, fibronectin fragments or CS-1 peptide RSA conjugates were identified as previously described (Wayner and Carter, 1987, supra; Wayner et al., 1989, supra). Briefly, a 48 well virig in styrene plate (Costar #3547) was coated with 5 ug/ml plasma fibronectin, fragment or peptide conjugate (with the final concentration of peptide being 5 ug/ml).
  • Na 2 51 CrO 4 -labeled cells were incubated with monoclonal antibodies to adhesion receptors for 15 min at room temperature and were then allowed to attach to the coated styrene substrates in the presence of the test antibodies for 30-60 min at 37°C.
  • test antibodies to adhesive ligands were pre-incubated with the substrates for 15 min before the test cells were added.
  • non-adherent test cells were removed by washing with PBS, and the adherent test cells were dissolved in 0.1N NaOH/0.25% SDS and bound 51 Cr counts per minute (cpm) were quantitated in a gamma counter.
  • test cells For peptide inhibition studies, 51 Cr-labeled test cells were pre-incubated with CS-1 derived peptides at various concentrations for 15 min at room temperature. The test cells were then allowed to attach to fibronectin-coated surfaces in the presence of exogenous test peptides for 30-60 min. The assay then proceeded as described above.
  • antibodies specific for epitopes on the ⁇ 4 subunit of the ⁇ 4 ⁇ 1 receptor complex inhibit T or B lymphocyte adhesion to plasma fibronectin, fragments of fibronectin containing adhesion sites in the Hep 2 domain, and fragment containing the first 25 amino acids (CS-1) or V (for variable) region (Wayner et al., 1989, supra; Garcia- Pardo et al., 1990, supra; Guan and Hynes, 1990, supra).
  • T Jurkat, FIGURE 1
  • B lymphoblastoid cell lines to surfaces coated with various fragments of fibronectin; in the presence of Mabs to inhibitory epitopes on ⁇ 4 or ⁇ 1.
  • the data in FIGURE 10 show that Jurkat cell adhesion to plasma fibronectin, CS-1, or fragments of fibronectin containing Hep 2 (58 kDa) and the entire CTCBD fragment (38 kDa) can be inhibited by Mabs to ⁇ 4 (P4C2) or ⁇ 1 (P4C10). This confirms the role of ⁇ 1 in mediating adhesion of cells to the Hep 2 site as well as to CS-1.
  • adhesion to the CCBD 80 kDa fragment
  • that contains the RGDS sequence is inhibited by Mabs directed to ⁇ 5 (P1D6) or ⁇ 1 (P4C10).
  • the Lymphocyte ⁇ 4 ⁇ l Receptor In CS-1 The Lymphocyte ⁇ 4 ⁇ l Receptor In CS-1.
  • the first step taken to define a minimal peptide ligand in CS-1 for the ⁇ 4 ⁇ 1 integrin receptor was to divide CS-1 into two smaller peptides, an N-terminal (A13) and a C-terminal (B12) peptide.
  • the ability of these (and smaller) peptides to inhibit Jurkat cell adhesion to substrates coated with intact fibronectin was examined (Table XIII).
  • CS-1 is a potent inhibitor of cell adhesion to fibronectin (Table I).
  • only the carboxy terminal B12 peptide is relatively effective in inhibiting T cell adhesion to intact fibronectin (Table XIII).
  • LDV was not as effective as B12 in inhibiting Jurkat-fibronectin adhesion.
  • Table XIE suggest that the minimal peptide ligand in CS-1 for the T lymphocyte ⁇ 4 ⁇ 1 receptor is glu-iso-leu-asp-val or EILDV. Identical results were obtained with a B lymphoblastoid cell line, Ramos and an identical pattern was observed for peptide inhibition of Jurkat or Ramos cell adhesion to CS-1-coated surfaces; deletion of the N-terminal glutamic acid and isoleucine residues resulted in a peptide with no inhibitory activity.
  • Adhesion of Jurkat T lymphoblastoid cells to plasma fibronectin, fragments of plasma fibronectin, or CS-1-rsa peptide-coated surfaces was tested in the presence of inhibitory anti-integrin monoclonal antibodies (Mabs) as follows (FIGURE 10): namely, 51Cr-labeled cells were incubated in the presence of the indicated Mabs (10 ug/ml purified antibody) for 10 min at ambient temperature and then allowed to attach to the protein or peptide coated-surfaces for 30 min (still in the presence of the inhibitory Mabs). Adhesion is expressed as % of control (i.e., a Protein G-purified non-immune mouse IgG).
  • the plasma fibronectin and the plasma fibronectin-fragments used are the same as those described herein (above).
  • Adhesion of various hematopoetic cell lines to CS-1 (open bars; FIGURE 12) or LDV minimal peptide-coated surfaces (cross-hatched bars; FIGURE 12) was tested as follows: Jurkat (T lymphoblastoid), A375 (melanoma), U937 (monocytic), Ramos (B lymphoblastoid), and ST-1 (EBV transformed B lymphoblastoid) cells were allowed to adhere to CS-1-rsa or LDVPST-rsa (5 ug/ml peptide) coated surfaces for 30 min at 37°C. At the end of this time the non- adherent cells were washed off and the adherent cells were solubilized in NaOH/SDS and quantitated in a gamma counter. The results are expressed as bound counts per minute.
  • CS-1 and a peptide containing EILDV were able to support the adhesion of Jurkat and A375 melanoma cells (FIGURES 11, Panel A and Panel B).
  • peptide conjugates containing EILDV (FIGURE 11, Panel B) or LDV also supported melanoma cell spreading.
  • Table XIV there were significant differences in the abili of CS-1 versus CS-1 derivative peptides to promote Jurkat cell adhesion.
  • truncated CS-1 peptides were inefficient mediators of hematopoietic cell adhesion and none of the truncated CS-1 peptide conjugates could support the adhesion of PHA activated T cell blasts.
  • FIGURE 12 The minimal peptide sequence required to support melanoma cell adhesion has been reported to be LDV (Mould et al., 1991, supra; Komoriya et al., 1991, supra).
  • the results presented in FIGURE 12 show that A375 melanoma cells adhered to LDVPST-coated surfaces, and of the hematopoietic cell lines tested only Jurkat cells adhered, and then only slightly, to surfaces coated with the LDVPST-RSA conjugate (FIGURE 12). Furthermore, some of the hematopoietic cell lines we examined, such as U937 or ST-1 cells adhered relatively poorly to surfaces coated with intact CS-1 (FIGURE 12).
  • FIGURE 13 A and 13B Jurkat
  • FIGURE 14A and 14B U937 cells
  • FIGURE 15 A and 15B HUT 78
  • FIGURE 13A and 13B adhesion of Jurkat cells to surfaces coated with pFN, CS-1, A13 or B12 derived peptide-rsa conjugates was tested in the presence of monoclonal antibody 8A2.
  • FIGURE 13A and 13B adhesion was tested in the presence of purified non-immune mouse IgG (5 ug/ml); and, in FIGURE 13B adhesion was tested in the presence of Mab 8A2 (5 ug/ml).
  • FIGURE 13A and 13B are expressed as counts per minute extracted from adherent cells.
  • FIGURE 15A adhesion was tested in the presence of purified non-immune mouse IgG (5 ug/ml); and, in FIGURE 15B adhesion was tested in the presence of Mab 8A2 (5 ug/ml).
  • FIGURE 15A adhesion was tested in the presence of purified non-immune mouse IgG (5 ug/ml); and, in FIGURE 15B adhesion was tested in the presence of Mab 8A2 (5 ug/ml).
  • HUT 78 cells 51 Cr-labeled HUT 78 cells were allowed to adhere to the peptide-coated surfaces in the presence of IgG or 8A2 for 30 min at 37°C. The rest of the adhesion assay proceeded as for FIGURE 12. Results are expressed as counts per minute extracted from adherent cells. Unlike U937 cells (above), HUT 78 cells adhere to LDV-coated surfaces without activation.
  • U937 (FIGURES 14A-B) cell populations are capable of interacting with CS-1 and LDV containing derivative peptides only after activation of the ⁇ 4 ⁇ 1 receptor complex with the 8A2 monoclonal antibody. Relatively few U937 cells, in fact, appear to adhere to any of the B12 derived peptides without activation of the ⁇ 4 ⁇ 1 receptor complex (FIGURES 14A-B). Since pretreatment of cells with 8A2 does not up-regulate expression of either ⁇ 1 or ⁇ 4 on U937 cells (supra), these data strongly suggest that recognition of the LDV sequence by ⁇ 4 ⁇ 1 requires an activation signal which can be transduced through ⁇ 1.
  • the Control as well as P4C10 or P4C2 treated cells were activated with 8A2.
  • P4C10 anti- ⁇ 1 and 8A2 anti- ⁇ 1 antibodies recognize functionally distinct epitopes on ⁇ 1 (Kovach, N.L., and J.M. Harlan, personal communication): i.e., 8A2 stimulates ⁇ 1-mediated adherence to VCAM-1 and P4C10 inhibits ⁇ 1-mediated b ⁇ nd ⁇ ig to VCAM or fibronectin.
  • Kinetic analysis of 8A2 activation of ⁇ 4 ⁇ 1 receptor complexes revealed that 8A2 induces rapid and stable U937 (or Jurkat) cell adhesion to LDV peptide-coated surfaces. Within 5 min. significant adhesion can be measured which peaks at 10-20 min. In some cell populations, such as Jurkat cells LDV recognition peaks within 5 min.
  • FIGURES 18A and 18B Adhesion of 72 hr PHA stimulated T cell blasts to pFN, CS-1, A13 or B12 and derivative peptide-coated surfaces was tested and the results are shown in FIGURES 18A and 18B.
  • adhesion was tested in the presence of purified non-immune mouse IgG (5 ug/ml); and, in FIGURE 18B adhesion was tested in the presence of Mab 8A2 (5 ug/ml).
  • These experiments were conducted as follows: 48 well plates were coated with 5 ug/ml (based on peptide weight) peptide-rsa conjugates overnight in PBS at 4°C.
  • lymphocyte integrin receptors can be activated to bind ligand with high avidity (Neugebauer and Reichardt, 1991, supra; Kovach, NX., and J.M. Harlan, personal communication). Activation of integrins in T lymphocytes can reportedly be achieved by cross-linking the T cell receptor (Dustin and Springer, 1989, Nature 341: 619-624; Shimizu et al., 1990, supra) or by incubating cells with monoclonal antibodies to ⁇ 1 (Kovach, supra.).
  • hematopoietic cell adhesion to CS-1 and derivative peptides was examined, herein, in the presence or absence of an antibody known to activate ⁇ 1. Resting hematopoietic cells that expressed the ⁇ 4 ⁇ 1 receptor complex bound the LDV peptide relatively poorly. Such cell populations were, however, able to hind LDV in the context of CS-1 or in some cases CS-1-B12. After activating ⁇ 1 with a monoclonal antibody that up-regulates ⁇ 1 function (i.e., 8A2; Kovach, supra) the minimal peptide ligand for the ⁇ 4 ⁇ 1 receptor complex in hematopoietic cells was determined (herein) to be LDV.
  • a monoclonal antibody that up-regulates ⁇ 1 function i.e., 8A2; Kovach, supra
  • the studies herein identify the LDV tripeptide as the minimal adhesive peptide in the CS-1 portion of the V region of fibronectin.
  • cells that express the high avidity form of the receptor appear to bind more readlly to LDV-coated surfaces.
  • the high avidity state of the receptor can be induced by preincubating cells with an activating monoclonal antibody to ⁇ 1 (e.g., 8A2 or P4B4; Coulter Immunologies). 8A2 activation of ⁇ 1 was rapid and did not result in an increase in cell surface ⁇ 1 expression. Resting peripheral blood T cells were not induced (under the present conditions) with 8A2 to bind LDV, while PHA stimulated T cells blasts could be.
  • LDV recognition by normal T cell may require at least two signals, e.g., one transduced through the T cell receptor (PHA activation) and the other via the integrin ⁇ 1 subunit (8A2). Since resting T cells, PHA blasts, HUT 78, and Jurkat cells do not demonstrate the same pattern or level of CS-1 peptide recognition, the findings herein suggest that malignant or activated T cells may express receptor complexes that can also vary in terms of basal ⁇ 4 ⁇ 1 activation. These findings are of significance to malignant T lymphocyte transformation and infiltration of organs such as the bone marrow, skin or brain in neoplastic or chronic inflammatory disease.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Procédé permettant de prévenir la migration de cellules exprimant le récepteur α4β1 à avidité élevée dans des tissus, et consistant à administrer un peptide essentiellement composé de LDV afin de prévenir l'adhésion des cellules exprimant le récepteur α4β1 à avidité élevée à une cellule ou à une matrice extracellulaire portant un ligand du récepteur α4β1.
PCT/US1992/011191 1991-12-24 1992-12-23 Inhibition competitive du recepteur alpha4-beta1 a avidite elevee a l'aide du tripeptide ldv WO1993012809A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81487391A 1991-12-24 1991-12-24
US814,873 1991-12-24

Publications (1)

Publication Number Publication Date
WO1993012809A1 true WO1993012809A1 (fr) 1993-07-08

Family

ID=25216225

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/011191 WO1993012809A1 (fr) 1991-12-24 1992-12-23 Inhibition competitive du recepteur alpha4-beta1 a avidite elevee a l'aide du tripeptide ldv

Country Status (2)

Country Link
AU (1) AU3420693A (fr)
WO (1) WO1993012809A1 (fr)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737204A1 (fr) * 1993-12-06 1996-10-16 Cytel Corporation Peptidomimetiques cs-1, compositions et procedes pour les utiliser
WO1997003094A1 (fr) * 1995-07-11 1997-01-30 Biogen, Inc. Composes inhibiteurs d'adherence cellulaire
US5688913A (en) * 1993-12-06 1997-11-18 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
EP0812920A1 (fr) * 1996-06-14 1997-12-17 Packard Instrument B.V. Utilisation de porphyrines dans une méthode de détection instrumental
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5821231A (en) * 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
US5936065A (en) * 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US6001573A (en) * 1996-06-14 1999-12-14 Packard Bioscience B.V. Use of porphyrins as a universal label
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US6239108B1 (en) 1996-07-11 2001-05-29 Biogen, Inc. Cell adhesion inhibitors
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6479492B1 (en) 1999-01-22 2002-11-12 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6495525B1 (en) 1998-05-28 2002-12-17 Biogen, Inc. VLA-4 inhibitor: oMePUPA-V
AU758886B2 (en) * 1995-07-11 2003-04-03 Biogen Idec Ma Inc. Cell adhesion inhibitors
US6552216B1 (en) 1996-07-25 2003-04-22 Biogen, Inc. Molecular model for VLA-4 inhibitors
US6630503B1 (en) 1999-08-13 2003-10-07 Biogen, Inc. Cell adhesion inhibitors
US6686350B1 (en) 1996-07-25 2004-02-03 Biogen, Inc. Cell adhesion inhibitors
US6875743B1 (en) 2000-11-28 2005-04-05 Biogen, Inc. Cell adhesion inhibitors
US7008949B2 (en) 2002-05-24 2006-03-07 Elan Pharmaceuticals, Inc. Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins
US7026328B2 (en) 2002-05-24 2006-04-11 Elan Pharmaceuticals, Inc. Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
JP2008013574A (ja) * 1995-01-23 2008-01-24 Biogen Idec Ma Inc 細胞接着インヒビター
US7452912B2 (en) 1999-01-22 2008-11-18 Elan Pharmaceuticals, Inc. Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
US7579466B2 (en) 2006-02-27 2009-08-25 Elan Pharmaceuticals, Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4
US7727996B2 (en) 2005-09-29 2010-06-01 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
US7763632B2 (en) 2005-09-29 2010-07-27 Elan Pharmaceuticals, Inc. Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
US8367836B2 (en) 2009-04-27 2013-02-05 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003252A1 (fr) * 1989-09-01 1991-03-21 Fred Hutchinson Cancer Research Center Inhibition de l'adhesion de lymphocytes sur l'endothelium vasculaire au moyen d'une nouvelle interaction entre le recepteur matriciel extra-cellulaire et son ligand

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003252A1 (fr) * 1989-09-01 1991-03-21 Fred Hutchinson Cancer Research Center Inhibition de l'adhesion de lymphocytes sur l'endothelium vasculaire au moyen d'une nouvelle interaction entre le recepteur matriciel extra-cellulaire et son ligand

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA vol. 88, no. 18, 15 September 1991, WASHINGTON DC, US pages 8072 - 8076 T. FERGUSON ET AL. 'Two integrin-binding peptides abrogate T cell-mediated immune responses in vivo.' *
THE JOURNAL OF BIOLOGICAL CHEMISTRY vol. 266, no. 6, 25 February 1991, WASHINGTON DC, US pages 3579 - 3585 A. MOULD ET AL. 'The CS5 peptide is a second site in the IIICS region of fibronectin recognized by the integrin alpha4beta1.' cited in the application *
THE JOURNAL OF CELL BIOLOGY vol. 116, no. 2, January 1992, CAMBRIDGE MA, US pages 489 - 497 E. WAYNER ET AL. 'Activation-dependent recognition by hemapoietic cells of the LDV sequence in the V region of fibronectin.' *

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117840A (en) * 1993-12-06 2000-09-12 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
EP0737204A4 (fr) * 1993-12-06 1999-06-23 Cytel Corp Peptidomimetiques cs-1, compositions et procedes pour les utiliser
US5688913A (en) * 1993-12-06 1997-11-18 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
EP0737204A1 (fr) * 1993-12-06 1996-10-16 Cytel Corporation Peptidomimetiques cs-1, compositions et procedes pour les utiliser
US5770573A (en) * 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5821231A (en) * 1993-12-06 1998-10-13 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using same
US6103870A (en) * 1993-12-06 2000-08-15 Cytel Corporation CS-1 peptidomimetic, compositions and methods of using the same
US5936065A (en) * 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
JP2008013574A (ja) * 1995-01-23 2008-01-24 Biogen Idec Ma Inc 細胞接着インヒビター
AU758886B2 (en) * 1995-07-11 2003-04-03 Biogen Idec Ma Inc. Cell adhesion inhibitors
CZ299054B6 (cs) * 1995-07-11 2008-04-09 Biogen Idec Ma Inc. Semipeptidový inhibitor bunecné adheze, farmaceutický prostredek, který ho obsahuje, a jeho použitípro výrobu léciva
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
WO1997003094A1 (fr) * 1995-07-11 1997-01-30 Biogen, Inc. Composes inhibiteurs d'adherence cellulaire
US6596687B1 (en) 1995-07-11 2003-07-22 Biogen, Inc. Cell adhesion inhibitors
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US6274556B1 (en) 1996-01-04 2001-08-14 Millennium Pharmaceuticals, Inc. Inhibitors of MadCAM-1-mediated interactions and methods of use therefor
US6001573A (en) * 1996-06-14 1999-12-14 Packard Bioscience B.V. Use of porphyrins as a universal label
EP0812920A1 (fr) * 1996-06-14 1997-12-17 Packard Instrument B.V. Utilisation de porphyrines dans une méthode de détection instrumental
US5998128A (en) * 1996-06-14 1999-12-07 Packard Instrument B.V. Use of porphyrins in instrumental detection methods
US6239108B1 (en) 1996-07-11 2001-05-29 Biogen, Inc. Cell adhesion inhibitors
US6686350B1 (en) 1996-07-25 2004-02-03 Biogen, Inc. Cell adhesion inhibitors
US6552216B1 (en) 1996-07-25 2003-04-22 Biogen, Inc. Molecular model for VLA-4 inhibitors
US6949534B2 (en) 1996-07-25 2005-09-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
US6495525B1 (en) 1998-05-28 2002-12-17 Biogen, Inc. VLA-4 inhibitor: oMePUPA-V
US6911439B2 (en) 1999-01-22 2005-06-28 Elan Pharmaceuticals, Inc. Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6479492B1 (en) 1999-01-22 2002-11-12 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6903088B2 (en) 1999-01-22 2005-06-07 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US7378529B2 (en) 1999-01-22 2008-05-27 Wyeth Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
US7538215B2 (en) 1999-01-22 2009-05-26 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6492372B1 (en) 1999-01-22 2002-12-10 Elan Pharmaceuticals, Inc. Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
US7005433B2 (en) 1999-01-22 2006-02-28 Elan Pharmaceuticals, Inc. Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
US7973044B2 (en) 1999-01-22 2011-07-05 Elan Pharmaceuticals, Inc. Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
US7452912B2 (en) 1999-01-22 2008-11-18 Elan Pharmaceuticals, Inc. Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
US7741328B2 (en) 1999-01-22 2010-06-22 Elan Pharmaceuticals, Inc. Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
US7049306B2 (en) 1999-01-22 2006-05-23 Elan Pharmaceuticals, Inc. Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4.
US7968547B2 (en) 1999-01-22 2011-06-28 Elan Pharmaceuticals, Inc. Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
US6949570B2 (en) 1999-01-25 2005-09-27 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
US7034043B2 (en) 1999-08-13 2006-04-25 Biogen Idec Ma Inc. Cell adhesion inhibitors
US6630503B1 (en) 1999-08-13 2003-10-07 Biogen, Inc. Cell adhesion inhibitors
US6875743B1 (en) 2000-11-28 2005-04-05 Biogen, Inc. Cell adhesion inhibitors
US7026328B2 (en) 2002-05-24 2006-04-11 Elan Pharmaceuticals, Inc. Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins
US7335663B2 (en) 2002-05-24 2008-02-26 Elan Pharmaceuticals, Inc. Heteroaryl compounds which inhibit leukocyte adhesion mediated by α4 integrins
US7135477B2 (en) 2002-05-24 2006-11-14 Elan Pharmaceuticals, Inc. Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins
US7008949B2 (en) 2002-05-24 2006-03-07 Elan Pharmaceuticals, Inc. Heterocyclic compounds which inhibit leukocyte adhesion mediated by α4 integrins
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
US7727996B2 (en) 2005-09-29 2010-06-01 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
US7763632B2 (en) 2005-09-29 2010-07-27 Elan Pharmaceuticals, Inc. Pyrimidinyl amide compounds which inhibit leukocyte adhesion mediated by VLA-4
US8158642B2 (en) 2005-09-29 2012-04-17 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
US8367688B2 (en) 2005-09-29 2013-02-05 Elan Pharmaceuticals, Inc. Carbamate compounds which inhibit leukocyte adhesion mediated by VLA-4
US7579466B2 (en) 2006-02-27 2009-08-25 Elan Pharmaceuticals, Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4
US7820687B2 (en) 2006-02-27 2010-10-26 Elan Pharmaceuticals, Inc. Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated by VLA-4
US8367836B2 (en) 2009-04-27 2013-02-05 Elan Pharmaceuticals, Inc. Pyridinone antagonists of alpha-4 integrins

Also Published As

Publication number Publication date
AU3420693A (en) 1993-07-28

Similar Documents

Publication Publication Date Title
US5730978A (en) Inhibition of lymphocyte adherence with α4β1-specific antibodies
AU654657B2 (en) Inhibition of lymphocyte adherence to vascular endothelium utilizing a novel extracellular matrix receptor-ligand interaction
WO1993012809A1 (fr) Inhibition competitive du recepteur alpha4-beta1 a avidite elevee a l'aide du tripeptide ldv
Wayner et al. Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin.
IE83907B1 (en) Inhibition of lymphocyte adherence to vascular endothelium utilizing a novel extracellular matrix receptor-ligand interaction
Matsuyama et al. Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex.
Holzmann et al. Peyer's patch‐specific lymphocyte homing receptors consist of a VLA‐4‐like alpha chain associated with either of two integrin beta chains, one of which is novel.
Carter et al. Epiligrin, a new cell adhesion ligand for integrin α3β1 in epithelial basement membranes
Hemler Adhesive protein receptors on hematopoietic cells
Akiyama et al. Analysis of fibronectin receptor function with monoclonal antibodies: roles in cell adhesion, migration, matrix assembly, and cytoskeletal organization.
CA2184493C (fr) Compositions inhibitrices de l'angiogenese et procedes correspondants
Gismondi et al. Human natural killer cells express VLA-4 and VLA-5, which mediate their adhesion to fibronectin.
De Strooper et al. Distribution of the beta 1 subgroup of the integrins in human cells and tissues.
Kern et al. Role of the I‐domain in collagen binding specificity and activation of the integrins α1β1 and α2β1
Chen et al. α2β1 integrin mediates dermal fibroblast attachment to type VII collagen via a 158-amino-acid segment of the NC1 domain
US7238668B1 (en) Inhibition of lymphocyte adherence with CS-1-peptides and fragments thereof
US5830678A (en) Method for identifying a target peptide that modulates the binding of epinectin ligand to integrin receptors
Yamada et al. Integrins in wound repair
WO1998016241A1 (fr) Procede servant a perturber l'adhesion cellulaire
WO1998016241A9 (fr) Procede servant a perturber l'adhesion cellulaire
Häkkinen et al. Altered interaction of human granulation-tissue fibroblasts with fibronectin is regulated by α5β1 integrin
Coito et al. EXTRACELLULAR MATRIX PROTEINS IN ORGAN TRANSPLANTATION1
Zhang et al. Restricted expression and function of laminin 1-binding integrins in normal and malignant oral mucosal keratinocytes
Kohn et al. Differential regulation of fibronectin receptor subunit gene and cell surface expression in human peripheral blood T lymphocytes.
Santoni et al. Fibronectin receptors on NK cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL RO RU SD SE

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载